US20090143713A1 - Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor - Google Patents
Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor Download PDFInfo
- Publication number
- US20090143713A1 US20090143713A1 US12/277,491 US27749108A US2009143713A1 US 20090143713 A1 US20090143713 A1 US 20090143713A1 US 27749108 A US27749108 A US 27749108A US 2009143713 A1 US2009143713 A1 US 2009143713A1
- Authority
- US
- United States
- Prior art keywords
- canceled
- gallbladder
- conduit
- lumen
- gastrointestinal tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
- A61B17/1114—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis of the digestive tract, e.g. bowels or oesophagus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/008—Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00278—Transorgan operations, e.g. transgastric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
- A61B2017/1139—Side-to-side connections, e.g. shunt or X-connections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/064—Blood vessels with special features to facilitate anastomotic coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2493—Transmyocardial revascularisation [TMR] devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/041—Bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M2025/0213—Holding devices, e.g. on the body where the catheter is attached by means specifically adapted to a part of the human body
- A61M2025/0233—Holding devices, e.g. on the body where the catheter is attached by means specifically adapted to a part of the human body specifically adapted for attaching to a body wall by means which are on both sides of the wall, e.g. for attaching to an abdominal wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1072—Balloon catheters with special features or adapted for special applications having balloons with two or more compartments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
Definitions
- Biliary disease includes conditions affecting the gallbladder, cystic duct, and common bile duct.
- Bile is a greenish-brown digestive fluid produced by the liver 10 illustrated in FIG. 1 , and is vital for the digestion of fatty foods. Bile is secreted by liver cells and collected by a network of ducts that converge at the common hepatic duct 12 . While a small quantity of bile drains directly into the lumen of the duodenum 30 (the section of small intestine immediately downstream of the stomach), most travels through the common hepatic duct 12 and accumulates in the lumen of the gallbladder 14 . Healthy gallbladders are pear-shaped sacs with a muscular wall that, on average, measure 10 cm in length and can store approximately 50 ml of fluid within its lumen.
- the hormone cholecystokinin is released, which causes the gallbladder 14 to contract. Contraction of the gallbladder 14 forces bile to flow from the gallbladder 14 , through the cystic duct 16 , into the common bile duct 18 , out the papilla 28 , and finally into the duodenum 30 of the small intestine. Here, it mixes and reacts with the food that exits the stomach.
- the Sphincter of Oddi 26 controls secretions from the liver, pancreas 24 , and gallbladder 14 into the duodenum 30 of the small intestine.
- the opening on the inside of the descending duodenum 30 after the Sphincter of Oddi 26 is called the major duodenal papilla 28 (of Vater).
- the biliary ducts, the gallbladder 14 , the cystic duct 16 and the common bile duct 18 comprise the biliary system ( FIG. 1 ).
- the pancreas 24 is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland (producing several important hormones, including insulin, glucagon, and somatostatin), as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.
- the pancreatic duct 22 or duct of Wirsung, is a duct joining the pancreas 24 to the common bile duct 18 to supply pancreatic juices which aid in digestion provided by the exocrine pancreas.
- pancreatic duct 22 joins the common bile duct 18 just prior to the major duodenal papilla 28 , after which both ducts perforate the medial side of the second portion of the duodenum 30 at the major duodenal papilla.
- gallstones a condition called cholelithiasis. Approximately 20 million Americans have gallstones, and about 1-3% will exhibit symptoms in any given year. In the U.S., gallstones are more common among women, with 25% of women having gallstones by the age of 60 and 50% by the age of 75. Pregnancy and hormone replacement therapy increase the risk of forming gallstones. Prevalence is lower for American men: approximately 25% will develop gallstones by the age of 75. In the U.S., gallstones are responsible for the highest number of hospital admissions due to severe abdominal pain.
- Gallstones 20 , 20 ′ are most often composed of cholesterol, but may also be formed from calcium bilirubinate, in which case they are called pigment stones. They range in size from a few millimeters to several centimeters, and are irregularly shaped solids resembling pebbles. They can form in the gallbladder 14 , cystic duct 16 , and/or the common bile duct 18 ( FIG. 2 ). By themselves, gallstones 20 do not necessarily result in disease states. This is the case 90% of the time.
- stones can cause infection and inflammation, a condition known as cholecystitis, which is generally the result of restricting or blocking the flow of bile from the gallbladder 14 and common bile duct 18 , or the fluids secreted by the pancreas 24 .
- Gallbladder disease may be chronic, and patients who suffer from this may periodically experience biliary colic. Symptoms include pain in the upper right abdomen near the ribcage, nausea, and/or vomiting. The pain may resolve within an hour of onset, may prove unresponsive to over-the-counter medicines, and may not decrease with changes of position or the passage of gas. Recurrence is common, with pain often recurring at the same time of day, but with frequency of less than once per week. Fatty or large meals may cause recurrence several hours after eating, often awakening the patient at night. Patients may elect to suffer from these symptoms for very long periods of time, such as years or even decades.
- Patients with chronic cholecystitis have gallstones and low-grade inflammation. Untreated, the gallbladder 14 may become scarred and stiff over time, leading to a condition called dysfunctional gallbladder. Patients who have chronic cholecystitis or dysfunctional gallbladder may experience gas, nausea, and abdominal discomfort after meals, and chronic diarrhea.
- Acute cholecystitis develops in 1-3% of those with symptomatic gallstone disease, and is due to obstruction of the common bile duct 18 or cystic duct 16 by stones or sludge. Symptoms are similar to biliary colic, though they are more severe and persistent. Pain in the upper right abdomen can be constant and severe, the intensity may increase when drawing breath, and it may last for days. Pain may radiate to the back, under the breastbone or the shoulder blades, and it may be perceived on the left side of the abdomen. In addition to nausea and vomiting, one third of patients experience fever and chills.
- Complications from acute cholcystitis can be serious and life threatening, and include gangrene, abscesses, perforation of the gallbladder 14 which can lead to bile peritonitis, pus in the gallbladder wall (empyema), fistulae, and gallstone ilius (when a gallstone creates a blockage in the small intestine).
- choledocholithiasis When gallstones 20 ′ become lodged in the common bile duct 18 ( FIG. 2 ), the condition is known as choledocholithiasis. Symptoms for this condition include pain, nausea and vomiting, and some patients develop jaundice, have dark urine and/or lighter stools, rapid heartbeat, and experience an abrupt drop in blood pressure. These symptoms can also be accompanied by fever, chills, and/or severe pain in the upper right abdomen. Complications from choledocholithiasis can also be very serious, and include infection of the common bile duct 18 (cholangitis) and inflammation of the pancreas 24 (pancreatitis).
- This condition called acalculous gallbladder disease
- acalculous gallbladder disease can also be chronic or acute.
- Chronic acalculous gallbladder disease also called biliary dyskinesia, is thought to be caused by motility disorders that affect the gallbladder's ability to store and release bile.
- Acute acalculous gallbladder disease occurs in patients who suffer from other serious illnesses which can lead to inflammation of the gallbladder 14 because of a reduction in the supply of blood to the gallbladder 14 or a reduced ability to contract and empty bile into the duodenum 30 .
- Gallbladder cancer can also develop in the gallbladder 14 , though this condition is rare.
- Gallstones have been found in 80% of patients with gallbladder cancer.
- Gallbladder cancer typically develops from polyps, which are growths inside the gallbladder 14 .
- polyps 15 mm across or larger When polyps 15 mm across or larger are observed, the gallbladder is removed as a preventive measure. Polyps smaller than 10 mm are widely accepted as posing low risk and are not generally removed.
- the 5-year survival rate is approximately 68%.
- gallbladder cancer is not usually detected until patients are symptomatic, by which time the disease is more advanced.
- cholecystectomy The most effective treatment for biliary disease has been surgical removal of the gallbladder 14 , a procedure called cholecystectomy.
- Surgical removal of the gallbladder 14 is indicated for patients who experience a number of less severe gallstone attacks, cholecystitis, choledocholithiasis, pancreatitis, acalculous biliary pain with evidence of impaired gallbladder 14 emptying, those at high risk for developing gallbladder cancer, and those who have previously undergone endoscopic sphincterotomy for common bile duct stones.
- Removal of the gallbladder 14 is highly successful at permanently eliminating biliary disease. Cholecystectomy is one of the most commonly performed procedures on women.
- the gallbladder 14 is not an essential organ, and after a period of adjustment post surgery, patients tend to return to more or less normal digestive function.
- Cholecystectomy can be performed either as open surgery, which requires a single larger incision in the upper right abdomen, or laparoscopic surgery, in which several small instruments are inserted through much smaller incisions in the abdomen. Approximately 80% of cholecystectomies are performed laparoscopically. The primary benefits of this minimally invasive approach are faster recovery for the patient, and a reduction in overall healthcare costs. Patients who receive laparoscopic cholecystectomy are usually released the same day. By contrast, patients receiving open cholecystectomies typically spend 5-7 days in a hospital before release.
- the degree of infection and inflammation prevents patients from undergoing immediate cholecystectomy.
- the gallbladder 14 must be treated with antibiotics and anti-inflammatory agents, and drained through a tube into a reservoir outside the abdomen. Placement of this tube occurs in a procedure called percutaneous cholecystostomy, in which a needle is introduced to the gallbladder 14 through the abdomen, fluid is withdrawn, and a drainage catheter is inserted. This catheter drains into an external bag which must be emptied several times a day until the tube is removed. The drainage catheter may be left in place for up to 8 weeks. In cases where no drainage catheter is inserted, the procedure is called gallbladder aspiration. Since no indwelling catheter is placed, the complication rate for gallbladder aspiration is lower than that of percutaneous cholecystostomy.
- Treatment methodologies other than cholecystectomy include expectant management, dissolution therapy, endoscopic retrograde cholangiopanctreatograpy (ERCP) with endoscopic sphincterotomy, and extracorporeal shockwave lithotripsy (ESWL).
- ERCP endoscopic retrograde cholangiopanctreatograpy
- ESWL extracorporeal shockwave lithotripsy
- Expectant management is appropriate for patients who have gallstones but no symptoms, and for non-emergency cases with less severe symptoms. This approach is not recommended when patients are in high risk categories (e.g. high risk for gallbladder cancer) or have very large gallstones (e.g. greater than 3 cm).
- high risk categories e.g. high risk for gallbladder cancer
- very large gallstones e.g. greater than 3 cm
- Oral dissolution therapy involves the administration of pills containing bile acids that can dissolve gallstones. This approach is only moderately effective, and the rate of recurrence of gallstones after completion of treatment is high. It is not appropriate for patients with acute inflammation or stones in the common bile duct (more serious conditions). Dissolution therapy tends to be more effective for patients with cholesterol stones, and is sometimes used in conjunction with lithotripsy. Despite its relative ineffectiveness, it is costly: treatment can last up to 2 years and the drugs cost thousands of dollars per year.
- contact dissolution a procedure that involves injection of a solvent such as methyl tert-butyl ether (MTBE) directly into the gallbladder 14 .
- MTBE methyl tert-butyl ether
- ERCP endoscopic retrograde cholangiopancreatography
- endoscope is introduced through the mouth of a patient, past the stomach to the papilla 28 , where the common bile duct 18 empties into the duodenum 30 .
- the overall goal of the procedure is to insert instruments and tools into the common bile duct 18 via the papilla 28 in order to treat biliary disease.
- endoscopic sphincterotomy is performed, which is a procedure that enlarges the opening of the papilla 28 in the small intestine. This can be accomplished surgically or via balloon dilation. Contrast agent is introduced into the common bile duct 18 to visualize the biliary tree fluoroscopically.
- Tools for clearing blockages such as mechanical lithotripsy devices, can be deployed to crush gallstones and remove the resulting debris. Drainage catheters and stents may also be inserted to facilitate the drainage of bile past obstructions. Complications from this challenging procedure occur at a rate of 5-8%, and include recurrence of stone formation, pancreatitis, infection, bleeding, and perforation.
- Extracorporeal shockwave lithotripsy is a technique in which focused, high-energy ultrasound is directed at the gallbladder 14 .
- the ultrasound waves travel through the soft body tissue and break up the gallstones.
- the resulting stone fragments are then usually small enough to pass through the bile duct into the small intestine.
- Oral dissolution therapy is often used in conjunction with ESWL. This treatment is not in common use, as less than 15% of the patient population are good candidates.
- ESWL is used to treat patients who are not candidates for surgery. Complications from ESWL include pain in the gallbladder area, pancreatitis, and failure of the gallstone fragments to pass into the small intestine.
- An aspect of the invention is directed to devices for treating biliary disease.
- Suitable devices comprise: a component configured for deployment between a gallbladder and a location within a gastrointestinal tract of a patient, the component having a proximal end and a distal end and a lumen extending therethrough.
- the devices can be configured for deployment by an endoscope, a needle, a guidewire, a guidance catheter, and/or a dilatation balloon.
- Endoscopes can further be adapted to comprise an ultrasound device.
- a system for treating biliary disease comprises a device for configuring a duct between a gallbladder and a gastrointestinal tract of a patient having a proximal end and a distal end with a lumen extending therethrough between.
- the devices can be configured to further comprise a delivery mechanism for delivering a substance. Deployment of these devices can, in some instances, cause a conduit to be formed between a gallbladder lumen and a target location within the gastrointestinal tract.
- a biliary disease treatment device comprising: an implant adapted to be delivered by an endoscope to a gastrointestinal site in proximity to a gallbladder, and further adapted to form a conduit between the gastrointestinal site and the gallbladder.
- the conduit can, for example, be formed between a lumen of the gallbladder and a target location within the gastrointestinal tract, such as proximal to a duodenum.
- Devices according to any one of the configurations disclosed can be formed from a bioresorbable material. Moreover, the devices can be removable and/or expandable. The devices can also be configurable in one or more configurations selected from a deployment configuration, a delivery configuration and a final configuration. Moreover, the devices can be configured such that a profile of the device changes between said configurations. Additionally, or in the alternative, a cross-sectional area of the device can be variable along a length of the devices. In some configurations a component or implant can be configured such that it has a flareable end, suitable flareable ends include ends that are generally hemispherical. Additionally, components or implants can comprise a configurable retainable feature.
- components or implants can comprise one or more clips configured to secure the components or implants at one or more positions.
- one or more fenestrations may be provided.
- the lumen or conduit can be configurable to provide restrictable fluid flow or to provide for a valve, such as a flow-restrictor or one-way valve. Any of the configurations of the device can be constructed such that the device is flexible.
- the system or device can also be configured to include a generally elongate tube that is adapted and configured to extend into the gastrointestinal tract. Configurations that include an elongate tube can be configured such that the tube is patent at a first end; the patent first end can be for placement adjacent the gallbladder.
- the elongate tube is not patent at a second end.
- the tube can be configured such that it has an adjustable length.
- one or more fluid control components can be provided to the designs.
- an enlargeable portion comprising two or more legs can be provided.
- kits for treating biliary disease comprising a duct forming component positioned between a gallbladder and a gastrointestinal tract.
- the kit can comprise any of the devices or systems described herein. Additionally, compounds can be provided for delivery to a tissue. Compounds or materials include, but are not limited to, for example, one or more of each of sclerosing agents, antibiotics, inflammatory agents, anti-inflammatory agents, biocompatible gels, and biocompatible foams. Additionally, a catheter, guidewire, needle, guidance catheter or balloon catheter can be provided. In some aspects, the kit can also include an ablation device.
- kits include, for example, one or more of each of a pair of scissors, a scalpel, a swab, a syringe, a hemostat, a lubricant, a needle, a snare, an antiseptic, and an anesthetic.
- a method of treating biliary disease comprises: (a) creating a duct or fistula between a gallbladder lumen and a portion of a gastrointestinal tract; and (b) providing for drainage from the gallbladder to the gastrointestinal tract. Additionally, the method can comprise the step of delivering a substance to the gallbladder via the duct. Additional method steps include delivering a device to the gallbladder through the duct. Suitable devices to be delivered include one or more of a stent, a drug-coated stent, a catheter, a needle, a guidance catheter, a balloon dilatation catheter and/or a guidewire.
- the step of creating the duct further comprises the step of inserting a device in communication between the gastrointestinal tract and the gallbladder lumen.
- the step of creating the duct between a gallbladder lumen and a portion of a gastrointestinal tract can further comprise the step of inserting a conduit between the gallbladder lumen and the portion of the biliary system.
- the method further comprises the step of forming a biological duct in situ from a patient's tissue.
- the step of inserting a conduit between the gallbladder lumen and the portion of the gallbladder tract can occur at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time.
- the methods can further comprise the step of providing a seal to prevent fluid from leaking into a peritoneum.
- the gallbladder can be defunctionalized in situ, such as by delivering a substance or material into a space within the gallbladder. Suitable substances or materials include, but are not limited to, gels and foams. In some instances, the delivered substances can be activated in situ.
- an amount of material can be delivered to fill, or substantially fill, the gallbladder lumen. Additionally, in some instances, the step of defunctionalizing is achieved by one or more of sclerosing or necrotizing a tissue within the gallbladder which can, for example, be achieved by an ablation technique.
- Still another aspect of the invention is directed to a method of delivering a device to treat biliary disease comprising: (a) using an endoscope to place a guidewire between an access lumen in a body and a gallbladder; (b) inserting a delivery catheter over the guidewire and into the gallbladder; (c) delivering a conduit on the catheter; and (d) positioning the conduit between the access lumen in the body and the gallbladder to create a lumen therebetween.
- the methods can also include the step of forming a biological duct in situ from a patient's tissue. Additionally, the step of positioning the conduit can occur at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time.
- Some methods can further comprise the step of passively retaining a distal end of the guidewire in the gallbladder while the guidewire is used to deliver additional elements.
- the methods include the step of retaining a distal end of the guidewire within the gallbladder.
- gallstones are removed through the created lumen.
- a substance is delivered to the gallbladder via the created lumen.
- the substance occupies the gallbladder lumen and can be one or more of antibiotics, inflammatory agents, and anti-inflammatory agents.
- Methods may also include preventing bile from entering the or a gallbladder lumen. Additionally, the gallbladder may be localized via endoscopic ultrasound, in some instances.
- the delivered conduit can be, for example, one or more of a stent, and a drug-coated stent.
- biliary disease is treated without removal of the gallbladder.
- a treatment area is visualized as part of the method.
- the conduit is anchored in place.
- the conduit is changed from a delivery configuration to a deployment configuration, from a delivery configuration to a final configuration or from a deployment configuration to a final configuration.
- Still other methods provide for reducing a cross-sectional profile of the conduit, providing a seal to prevent fluid from leaking into a peritoneum, and/or restricting fluid flow from the gallbladder lumen to the gastrointestinal tract.
- Other methods include operating a valve to restrict fluid flow.
- FIG. 1 illustrates an overview of the biliary system
- FIG. 2 illustrates the biliary system with gallstones
- FIG. 3 illustrates an endoscope accessing the biliary system via the intestinal system
- FIGS. 4A-D illustrate embodiments of a device adapted to provide a conduit between two body lumens
- FIGS. 5A-B illustrates the outward radial force applied by an embodiment of a device adapted to provide a conduit between two body lumens
- FIGS. 6A-B illustrates an embodiment of a device with a retaining feature
- FIGS. 7A-G illustrate variations of retaining features
- FIGS. 8A-B illustrate another variation of a retaining feature
- FIGS. 9A-C illustrates a delivery configuration which reduces cross-sectional area
- FIGS. 10A-B illustrates an alternate embodiment of a device
- FIG. 11 illustrates an alternate embodiment of a device having an elongate tube
- FIGS. 12A-C illustrate an alternate embodiment formed from shape memory material
- FIGS. 13A-G illustrate a close-wound spring embodiment of the device
- FIGS. 14A-B illustrates a stent-like embodiment
- FIGS. 15A-B illustrate retaining features
- FIGS. 16A-E illustrate a variety of valve embodiments
- FIGS. 17A-B illustrate a variety of plug embodiments
- FIGS. 18A-I illustrate delivery of a device according to the invention via a catheter
- FIG. 19 illustrates the steps of delivering a device according to the invention via a catheter
- FIG. 20 illustrates delivery of a device according to the invention at the distal tip of an endoscope
- FIGS. 21A-H illustrate a guidewire retention feature
- Devices, systems, methods and kits provided herewith can obviate the need for a plurality of procedures, including, for example: 1) percutaneous cholecystostomy, 2) cholecystectomy, 3) percutaneous trans-hepatic cholangiography (PTHC), and 4) endoscopic retrograde cholangiopancreatography (ERCP).
- disclosed treatment modalities enable treatment of a distal common bile duct 18 obstruction, e.g. secondary to pancreatic carcinoma, cholagiocarcinoma, and/or ampullary carcinoma.
- the conventional standard of care for treating biliary disease has been surgical removal of the gallbladder 14 and closure of the cystic duct 16 .
- the present invention seeks to accomplish the same end in a less invasive and less costly way. This may be achieved by treating biliary disease without requiring the removal of the gallbladder 14 .
- Methods and apparatus are described in this application that are intended to effectively treat biliary disease with the gallbladder 14 and cystic duct 16 left in situ by providing a shunt to the gallbladder.
- a method of treating biliary disease involves using an endoscope 310 to access a region 350 in the gastrointestinal (GI) tract ( FIG. 3 ) to which the gallbladder 14 is in close proximity, locating the gallbladder 14 , accessing the gallbladder 14 , and then treating the underlying condition that led to the need for intervention ( FIG. 3 ).
- Treatments may also include, but are not limited to: providing for drainage of the gallbladder 14 and/or the biliary tree, delivering suitable materials or substances, such as antibiotics, inflammatory, anti-inflammatory agents (any of which may be short-term acting, fast acting, or time release), and/or other substances (e.g.
- the gallbladder can be accessed by any suitable mechanism or procedure including, percutaneously, endoscopically, laparascopically, and the like. Moreover, any of the materials and substances delivered to the gallbladder can be delivered concurrently or sequentially. Delivery of substances can occur sequentially in time or the sequence of delivery can be separated by seconds, minutes, or hours.
- Localization of the gallbladder 14 can be performed via endoscopic ultrasound (EUS) by accessing the wall of the GI tract with an endoscope 310 as shown in FIG. 3 . Localization may also be achieved by any other method that visualizes anatomical features, such as fluoroscopy, x-rays, magnetic resonance imaging (MRI), computed axial tomography (CT) scans, ultrasound imaging from outside the body, or any method of anatomical imaging and visualization.
- EUS endoscopic ultrasound
- MRI magnetic resonance imaging
- CT computed axial tomography
- the gallbladder 14 may be accessed and/or treated 350 through the wall of the GI tract (or any lumen in proximity to the gallbladder 14 ) with tools and devices (e.g. needles, guidewires, guidance catheters, dilators, etc.) delivered through, for example, an endoscope 310 .
- tools and devices e.g. needles, guidewires, guidance catheters, dilators, etc.
- Such tools and devices may be inserted down the length of the endoscope's working channel 312 , or loaded onto or near the distal end of the endoscope 310 .
- tools and other devices may be used that do not require the aid of the endoscope for navigation or delivery.
- Direct visualization may be provided by the endoscope 310 during the procedure, as well as irrigation, suction, and insufflation.
- any lumen in close proximity to the gallbladder 14 is a candidate for access to and treatment of the gallbladder 14 and other members of the biliary system.
- in situ treatment of the gallbladder 14 is enabled via the creation of a passageway between the gallbladder lumen and a lumen in close proximity, e.g. at or near the duodenum.
- This passageway or duct may be created by an implantable device 420 , such as those illustrated in FIG. 4 .
- the passageway may be temporary or permanent. It may be thought of as a fistula that is intentionally created between the gallbladder 14 and another lumen in proximity, as described above. Alternately, it may be thought of as a stoma between the gallbladder 14 and another lumen in proximity.
- the passageway serves as a conduit, an access port, through which a number of actions may be accomplished, drainage may be achieved, and treatments may be delivered.
- a device 420 forming the passageway may be left in the patient for a short period of time, such as a few hours, a few days or a few weeks, or it may be left in place for extended periods of time, such as several weeks, months, or years.
- the device 420 may also be left in place permanently. If it is left in place long-term, tissue may form around the device 420 , creating a fistula that connects the gallbladder 14 to the access lumen which may persist even if the passageway device 420 is removed, thus forming a biological in situ device 420 from the patient's own tissue.
- the fistula may be beneficial and useful, as it may continue to allow drainage for the contents of the gallbladder 14 into the small intestine.
- a fistula may remain open for a period of time and then close on its own, and may pose no additional risk and prove to be an acceptable course of events. Whether the device 420 is left in place or removed, and whether the fistula is left open or closed, evidence at the site may serve to mark the location of treatment in the event of future procedures.
- the cross-sectional area presented by the device 420 at various locations may be reduced, thus, for example, reducing its overall profile.
- the configuration of the device 420 is caused to change, it may be helpful to conceive of the device 420 having one or more configurations, for example: one configuration when it is delivered (a “delivery configuration”), another configuration when it is deployed (a “deployment configuration”), and yet another configuration when it is in place and functional (a “final configuration”). Still other configurations may also be necessary or useful.
- delivery configuration it may be advantageous to alter (e.g.
- the configuration of the device 420 may be altered so that placement into the patient is facilitated. This may be different from both the delivery configuration and the final configuration, though this is not necessarily the case. As will be appreciated by those skilled in the art, one or more configurations can be the same or substantially the same.
- the preferred embodiment of the conduit is that of a short tube that is flared into hemispherical bowl-like shapes at both ends, as depicted in FIG. 4 .
- the flared bowl-like shapes at the distal end 422 and the proximal end 425 secure the conduit device 420 in the desired location within the gallbladder 14 and the access lumen, e.g. the duodenum 30 .
- the conduit 420 forms the proposed passageway 424 between the gallbladder 14 and the body lumen from which it will be accessed, such as through the duodenum 30 .
- the tubular portion 430 of the conduit 420 is typically about 4-10 mm in length h 1 , with an inner diameter w 1 of the device lumen or passageway 424 large enough to facilitate drainage and access, typically in the range of 2-10 mm.
- the outer diameter of the tubular portion 430 of the conduit 420 is typically larger than about 3 mm (10 French) in its final configuration.
- a variation of the preferred embodiment, depicted in FIG. 4B comprises a short tube which is bent at an angle, rather than straight, which may beneficially accommodate anatomical variations.
- FIG. 4C comprises a longer tube which may allow for relative motion between the gallbladder and the connected lumen, while maintaining patency of the conduit.
- This configuration may optionally include additional retaining features: a first 415 which is proximal to the distal retaining feature 422 and a second 419 which is distal to the proximal retaining feature 425 .
- These additional retaining features serve to secure the tissue of the gallbladder wall and the connected lumen (e.g. the wall of the duodenum) and prevent leaks even as the structures undergo relative motion.
- the tube comprises a series of loops so that the distance h 1 between the distal retaining feature 422 and the proximal retaining feature 425 may change without applying excessive force to the tissue adjacent to the anchors.
- the tubular portion 530 may have radial compliance so that it presses gently but positively outward against the tissue it penetrates.
- the tissue will squeeze down around the device 520 as the tube 530 generates outward radial force F. This will facilitate sealing, and prevent bile and/or other fluids from leaking into the peritoneum.
- the flared features 422 and 425 serve to secure the conduit 520 in place, as well as provide slight tension to approximate the gallbladder 14 wall to the wall of the body lumen providing access.
- the soft and compliant nature of the preferred materials also provide for a measure of relative motion between the gallbladder 14 and connected lumen, which may increase the comfort of the patient.
- These retaining features 422 and 425 at either end of the device 420 have preferred dimensions of approximately 25 mm diameter at their widest point w 2 , and are approximately hemispherical in shape so that their effective height h 2 is approximately 12.5 mm. They may be co-molded or made as one piece together with the tubular portion 430 .
- a variation on this embodiment includes an integral retaining feature 622 on one end of the device's tubular portion 630 , but does not include it on the opposing end as shown in FIG. 6 .
- the integral retaining feature 622 is compressed down to a minimal profile for delivery, and then allowed to expand outward during deployment.
- a retaining clip 628 may be added over the end of the tube 630 that has no integral retaining feature.
- the retaining clip 628 may have a single location on the tube 630 where it is securable, or it may be adjustable so that the clip 628 may be secured in a variety of locations 631 . This provides for adjustability of the compression applied to the walls of the body lumens approximated by the conduit 620 (the gallbladder wall and the wall of the adjacent lumen, such as at or near the duodenum 30 ).
- the retaining feature 422 and 425 located at either one end (as illustrated in FIG. 6 ) or both ends (as illustrated in FIG. 4 ) of the tubular portion 430 of the device 420 may be embodied in a number of different shapes.
- the hemispherical flared retaining feature 422 provides a measure of separation between the entry of the tubular portion 430 of the conduit 420 and the body lumen in which it resides. This may be useful in cases where it is undesirable for the contents of the body lumen to enter the conduit 420 directly (e.g. inside the duodenum 30 , it may be undesirable for partially digested food to enter the conduit 420 ).
- this bowl shaped retaining feature 422 When this bowl shaped retaining feature 422 is suspended upside down or sideways, it is especially effective at preventing ingress of undesirable matter.
- other configurations that provide less separation between the conduit 420 and the body lumen may be useful.
- Other designs may allow for less restricted flow of fluid from within a body lumen into the lumen of the conduit 420 . This may be useful, for example, inside the gallbladder 14 , where complete drainage of bile may be beneficial.
- An alternate embodiment based on the previously-described hemispherical shape is that of a bowl 722 with slots 732 ( FIG. 7A ).
- Another embodiment is a hemispherical shape 722 that has apertures or holes 734 incorporated into it so that it is fenestrated ( FIG. 7B ).
- the incorporation of fenestrations may be applied to any shape to allow for flow, e.g. globes, tubes, etc.
- Shapes other than hemispherical bowls may also have useful properties.
- One such embodiment is that of a flat, or nearly flat, plate as an anchoring feature 722 . This is illustrated in FIG. 7 C( 1 ).
- One advantage of this flat or nearly flat shape is that most or all of the fluid inside the lumen where it resides (e.g. the gallbladder 14 ) may pass into the conduit 720 , and there will be little or no void or dead space where fluids may pool and fail to flow.
- the edges of a flat or nearly flat retaining feature may be rounded or curled up slightly in order to prevent trauma to adjacent tissue, FIG. 7 C( 2 ).
- FIG. 7D Another variation of the shape of the anchoring or retaining feature 722 is configured so that it resembles lines of longitude of a globe, as shown in FIG. 7D .
- at least two legs 738 , 738 ′ are included (forming a complete circle), but four or more legs may be incorporated (forming two or more circles). Odd numbers of legs 738 may be incorporated, with the semicircles joined at the base 721 (the connection to the tube) and the apex 723 (the location farthest from the tube).
- the apex 721 may be pushed away from the tube 730 , which will collapse the globe shaped retaining feature 722 into a linear configuration. This may be achieved with the use of a wire (not shown) or any other element which may push the apex 721 away from the tube 730 .
- Another embodiment of the retaining feature 722 at the end(s) of the conduit's tubular portion resembles the shape and organization of a flower's petals 740 .
- the petals 740 are joined at the point where they contact the tube 730 (similar to the flower's stem), and spread outwards when unconstrained, as shown in FIG. 7E .
- a device 720 has a retaining feature 722 that resembles the extensible portions of a drywall anchor or toggle, as shown in FIG. 7F .
- the retaining feature's default (unconstrained) configuration is fully extended, so that the cross-sectional area is reduced.
- the apex 723 of the extensible portions of the retaining feature may be drawn in towards the tubular portion 730 of the conduit 720 , spreading out a set of legs 738 in the process.
- the apex 723 may be drawn in by pulling on a wire (not shown), for example, or any other element adaptable to apply tension at the apex 723 .
- the retaining feature's default (unconstrained) configuration may be fully contracted, so that the cross-sectional area is maximized.
- a wire or similar element may be used to push the apex 723 away from the tubular portion 730 of the conduit 720 to reduce the cross-sectional area for delivery.
- a retaining feature 722 has an increase in the outer diameter of the tube 730 comprising the conduit 720 ( FIG. 7G ).
- This embodiment may be configured to have a consistent outer diameter during delivery and deployment, and then configured to have an increased outer diameter for its final configuration 722 , which serves to secure the conduit 720 within the body lumen.
- the device 820 is shaped in such a way that it may be pushed through a wall of a body lumen or lumens directly, and then rotated into position along with the conduit 820 , to secure the two body lumens together and hold the conduit 820 in place, as illustrated in FIG. 8A .
- the retaining feature in this embodiment may be divided into more than one element 822 , 822 ′ and 825 , 825 ′, and these elements 822 ′, 825 ′ may be rotated radially to better secure the conduit 820 once it is in position.
- pairs of elements 822 , 822 ′ and 825 , 825 ′ are spread out to hold the conduit 820 in place, however any number of elements 822 and 825 greater than or equal to one could be used without departing from the scope of the invention.
- a method for altering the configuration of the device 920 to facilitate delivery is to elongate the device 920 . If the device 920 is sufficiently elongated, the cross-sectional area will be reduced, in some cases substantially. Once the device 920 has been elongated and its cross-sectional area reduced, it may be loaded into a sheath, capsule, or other dimensional retaining component 942 so that this low profile configuration is maintained until it is desirable to alter the configuration, such as when the device 920 is deployed or delivered in situ. Alternately, the device 920 may be compressed or elongated and then constrained by tightly wrapping or tying it with string or wire.
- Suitable materials for these techniques include, but are not limited to, shape memory alloys (SMA) such as Nitinol®, and cross-linked polyethylene.
- SMA shape memory alloys
- Another means of altering the configuration of the device 920 to facilitate delivery is to construct it so that its initial shape is that of a series of loops resembling a corkscrew, FIG. 9B .
- the device may be straightened and then constrained for delivery, or it may be rotated into the preferred position once the distal end has been inserted through the walls of the lumens.
- This configuration may incorporate at least one loop ( FIG. 9C ), and tissue may be retained and constrained between any two adjacent loops 922 and 931 .
- the conduit may be made of any suitable biocompatible material that is elastic and soft. Silicone is the preferred material. Other materials may optionally be used, e.g. polytetrafluoroethylene (PTFE), expanded PTFE, other members of the fluoropolymer family, urethanes, polyurethanes, and others.
- PTFE polytetrafluoroethylene
- expanded PTFE expanded PTFE
- the materials can, for example, be soft at body temperature, with durometer typically in the range of 20-60 A. Softer materials are easier to deliver and reduce the risk of injury to adjacent tissue.
- a suitable material is, for example, soft enough to compress to a compact size for delivery and deployment.
- Embodiments of retaining features 722 , 822 may be comprised of compliant polymeric material (e.g. silicone). If they are comprised of soft, compliant materials, the retaining features 722 , 822 can readily bend and deform to accommodate the passage of large items through the conduit 724 , 824 formed between a first body lumen and a second body lumen, e.g. the gallbladder 14 and the duodenum 30 . Alternately, the retaining features 722 , 822 may be formed from less compliant material or a metal (e.g. Nitinol or stainless steel).
- a metal e.g. Nitinol or stainless steel
- the retaining features 722 , 822 may be formed integrally with other elements of the overall conduit device 820 , such that the components are formed to act in a unified manner by formation as a single component, or may be separate from the other elements of the overall conduit device 820 .
- the retaining features 722 , 822 may be incorporated into the overall assembly during manufacturing, or the parts may be installed by a clinician user prior to use in a patient or during deployment of the device 820 within a patient.
- the device 820 may also be comprised of a biodegradable, bioabsorbable, or resorbable material, in which case it may dissolve within the mammalian body within a desirable and useful length of time. This could eliminate the need for follow-up procedures to remove the device 820 at the end of a course of treatment. Manufacturing the device 820 from such a material may not prevent clinicians from actively removing it if the need arose, however. Rather, it would prevent the need to actively remove it in cases where no other treatment was required.
- the conduit 1020 may be comprised of a single component and a single material, or it may be an assembly of different components, some of which may be of different materials that are integrally formed to act or perform in a unified manner once deployed.
- a conduit 1020 may be comprised of an SMA spring form 1052 , over which silicone 1054 (or another suitable polymer material) is molded as illustrated in FIG. 10 .
- the spring form 1052 serves to lend the conduit structure and dimensional stability, while the silicone (or other polymer) outer shell 1054 creates soft surfaces which are unlikely to cause injury to tissue and facilitate sealing of the device 1020 in situ and prevent leaks.
- SMA materials are used, their transition temperatures can be selected to be slightly below body temperature, so that they can be designed to hold one shape for delivery and deployment, and, after transitioning, they will have the desired shape(s) for optimizing the function of the conduit.
- the SMA material may be used in its superelastic state.
- an alternate embodiment of the conduit device 1120 is formed from an elongate tube 1130 which incorporates a retaining feature 1122 to secure a distal end 1102 (the end within the lumen of the gallbladder 14 ), a distal end 1102 with sufficient structure to maintain the conduit tube's 1130 patency, a proximal end 1104 that may lack sufficient structure to maintain the conduit tube's patency, and/or an overall length L 1 sufficient to deliver bile from the gallbladder 14 into the duodenum 30 a length downstream of the location that the duodenum 30 and the gallbladder 14 are connected by the conduit 1120 .
- the tube 1130 may be thought of as highly flexible so that it may be easily moved and/or deformed by materials such as chyme 1139 moving through the small intestine. Downstream delivery of bile into the duodenum 30 may be desirable to prevent bile reflux, a condition that occurs when bile enters the patient's stomach and/or esophagus.
- the length of the tube 1130 may be adjustable.
- the conduit may be placed into the gallbladder 14 and then trimmed to the desired length.
- the conduit 1120 may be made available to clinicians in a variety of lengths.
- conduit device 1220 is comprised entirely of SMA, such as Nitinol.
- the radial dimensions of the conduit's tubular portion 1230 may be reducible to facilitate delivery. Methods of achieving this include, but are not limited to: cutting the tube wall parallel to its central axis x and rolling the material tightly to reduce the diameter d for delivery, then expanding it to a greater diameter D and rejoining the edges to form a complete and sealed tubular structure at deployment; simply folding or radially collapsing the tube 1230 to a smaller outer diameter d 1 which may be the minimum possible radial dimension from which the SMA material can fully recover its desired tubular diameter d 2 and shape at deployment ( FIG.
- the tube 1230 into a polygon which, in its collapsed configuration folds in an “asterisk” pattern to present minimal cross-sectional area with diameter d 1 , and in its expanded configuration is a polygon approximating a circular cross-section with diameter d 2 ( FIG. 12C ).
- the number of sides of the polygon can vary, with higher numbers of sides resulting in beneficial characteristics such as the device 1220 more closely approximating a circular cross-section when expanded and collapsing to smaller sizes to facilitate delivery and deployment.
- FIG. 13 an alternate embodiment is depicted that may be comprised entirely of SMA or other material is that of a close-wound spring.
- the spring 1352 may be formed by tightly coiling a wire-shaped material, such as Nitinol, other SMA material, stainless steel, titanium, or other suitable material so that it forms a coil as shown in FIG. 13A .
- This coil 1352 shares characteristics with an extension spring: if tension is applied at the ends of the component, the coils are caused to separate, and this results in the spring creating a compressive return force F. When no external tension is applied to the coil, the gaps between the individual winds of the coil are minimal, and these gaps may be maintained by residual compressive forces imparted to the material during manufacturing as shown in FIG. 13B .
- a tensile load F may be applied, and/or the proximal and distal ends of the spring may be rotated relative to each other T, greatly increasing the length of the device 1320 , decreasing the cross-sectional area and diameter d accordingly as shown in FIG. 13C .
- the device 1320 Once the device 1320 is in the desired configuration for delivery, it may be loaded into a sheath or other retaining component as shown in FIG. 13D so the configuration is maintained until it is desirable to alter the configuration, such as when the device 1320 is deployed.
- a variation of this embodiment includes a coating 1354 of the material comprising the spring 1352 with a soft, easily deformable polymeric material, such as (but not limited to) silicone, PTFE, or EPTFE as illustrated in FIG.
- This coated spring device 1320 has the characteristics described above, as well as the advantages of a soft, compliant, sealed surface: e.g. the potential for bile leaks is reduced (as well as other fluids), and a reduction of the likelihood of injury to surrounding tissue by the device 1320 or the acts of delivering and deploying the device 1320 .
- the spring 1352 could be located outside the soft, compliant material 1354 , as illustrated in FIG. 13F , or inside, as illustrated in FIG. 13G .
- the structure of the conduit's tubular portion 1430 may be comprised of SMA (such as Nitinol or other suitable material) or non-SMA material (e.g. stainless steel or polymeric material) in the form of a stent as shown in FIG. 14 .
- the stent 1420 may be covered or may cover another material (such as silicone or EPTFE, as described above) so that it provides a sealed passageway between the gallbladder 14 and the connected body lumen.
- the stent 1420 presents a very small cross-sectional area with initial outer diameter d.
- the stent 1420 is caused to expand outwards against the hole in the walls of the body lumens it connects together. This outwards, radial force of the device 1420 and increase in outer diameter D may be optimized in such a way as to reduce the risk of leaks between the gallbladder 14 , the connected body lumen, and the surrounding anatomy.
- Leaks may also be prevented by coating the external surfaces of any conduit design with a suitable adhesive, such as one that is biocompatible. Such an adhesive serves to bond the device 1420 to the tissue it contacts, and prevents gaps which may otherwise allow fluid to escape from either lumen or the conduit itself.
- a suitable adhesive such as one that is biocompatible.
- the conduit's retaining features 1522 located at either end may also be comprised of SMA (e.g. Nitinol) or other suitable non-polymeric material. This may be the case whether the tubular portion 1530 of the conduit 1520 is formed from the same or from different materials.
- SMA e.g. Nitinol
- Such retaining features may take on a number of shapes and configurations.
- FIG. 15A shows one embodiment in which the retaining features 1522 resemble spring form fingers 1558 , spread out in a flared pattern from the ends of the conduit's tubular portion. During delivery, the fingers 1558 are compressed in towards the central axis x of the tube 1530 to reduce the profile. Upon deployment, the fingers 1558 are allowed to spread outwards to function as a retaining feature 1522 .
- the retaining feature 1522 comprises an element 1558 in a spiral configuration that resembles a corkscrew, with a variable outer diameter. During delivery, this spiral is compressed to reduce its profile, and upon delivery it is caused to expand outwards to serve the purpose of retention.
- a valve 1660 may be incorporated into or attach onto the conduit device 1620 .
- it may be desirable to deliver bile into the digestive tract, and to drain pus or other fluids, but undesirable for partially digested food to move from the small intestine into the gallbladder 14 .
- a valve may be used to prevent flow into the gallbladder 14 from sources other than the biliary system. This is illustrated in FIG. 16 .
- the valve 1660 allow the movement of material from the gallbladder 14 into the body lumen (e.g.
- a duodenum 30 connected by the conduit 1620 , prevent flow in the reverse direction, and control the level of pressure that is allowed to develop within the gallbladder 14 .
- the valve 1660 may be incorporated or added at any location within the conduit, from the most distal end (the farthest end inside the gallbladder 14 ) to the most proximal end (the closest end inside the connected lumen), as shown in FIG. 16A .
- the valve may be made of any suitable material, such as the materials used to construct the conduit.
- the preferred material for this purpose is silicone.
- it may also be made of any other suitably biocompatible compliant material (in cases where bending characteristics of the material are used to create the flow control feature) or non-compliant material such as stainless steel, nickel-titanium alloy, or titanium (in cases where mechanical elements are used to create the flow control feature).
- the preferred embodiment is that of a duckbill valve illustrated in FIG. 16B , with a slit in a cone-shaped compliant material that supplies elastic forces that cause it to be closed under normal circumstances, open when the pressure in the gallbladder 14 exceeds the pressure in the connected lumen (e.g.
- the valve may be designed as a sprung flap ( FIG. 16C ), with functional characteristics similar to those of the duckbill valve described above.
- FIG. 16D Another embodiment is that of a bicuspid valve ( FIG. 16D ) or tricuspid valve ( FIG. 16E ), which also exhibit the characteristics of allowing flow from the gallbladder 14 into the connected body lumen, but not in the reverse direction.
- Each of these embodiments, and other valve embodiments not specifically described herein, share the flow control characteristics of a) allowing flow from the gallbladder 14 into the body lumen connected through the conduit 1620 when the pressure in the gallbladder 14 is greater than the pressure in the connected lumen by a desired amount, b) not allowing flow from the connected lumen into the gallbladder 14 when the pressure in the lumen exceeds the pressure in the gallbladder 14 , and c) not allowing flow between the gallbladder 14 and the connected lumen when little or no pressure differential exists between the two bodies.
- An adjustable valve 1660 may also be incorporated into or added to a conduit 1620 .
- a valve would enable practitioners or patients to adjust the difference in pressure between the gallbladder 14 and the connected lumen (such as the duodenum) at which the valve opens.
- Adjustability may be incorporated into the valve body in such a way that a clinician may adjust it endoscopically, or it may be incorporated in such a way that a clinician or the patient may adjust the valve without requiring additional endoscopy or invasive procedure.
- Another approach to controlling flow between the gallbladder 14 and a connected body lumen is to incorporate or allow for the installation of a blocking mechanism or plug to close off the conduit. This may be in addition to, instead of, or interchangeable with a valve 1660 , as described above.
- the plug may allow for temporary or permanent blockage of the passageway between the gallbladder 14 and the connected body lumen created by the conduit.
- One embodiment of such a plug is as a diaphragm 1770 or membrane ( FIG. 17A ) that allows for short term access to the gallbladder 14 through the conduit by puncturing the material at the center of the block. This may be accomplished, for example, with a needle or fine catheter.
- the material of the diaphragm or membrane may be selected so that it is self-healing, and as such is re-sealable. This may allow for multiple instances of puncture and hence able to be used for repeated access.
- Another embodiment of such a plug 1770 is that it is installable, removable and/or replaceable ( FIG. 17B ). These functions may be performed endoscopically.
- any of the materials and substances delivered to the gallbladder can be delivered concurrently or sequentially. Delivery of substances can occur sequentially in time or the sequence of delivery can be separated by seconds, minutes, or hours.
- An amount of fluid, gas, or material delivered as described throughout can be such that it fills the gallbladder, substantially fills the gallbladder (e.g., fills more than 50% of the gallbladder, more than 75% of the gallbladder, more than 85% of the gallbladder, more than 90% of the gallbladder, more than 95% of the gallbladder, or more than 99% of the gallbladder) or is activatable to fill or substantially fill the gallbladder.
- substantially fills the gallbladder e.g., fills more than 50% of the gallbladder, more than 75% of the gallbladder, more than 85% of the gallbladder, more than 90% of the gallbladder, more than 95% of the gallbladder, or more than 99% of the gallbladder
- the amount of fluid, gas, or material delivered as described throughout can be such that it coats the interior lumen of the gallbladder, or substantially coats the interior lumen of the gallbladder (e.g., coats more than 50% of the gallbladder, more than 75% of the gallbladder, more than 85% of the gallbladder, more than 90% of the gallbladder, more than 95% of the gallbladder, or more than 99% of the gallbladder).
- FIG. 18 An examplar delivery method is shown in FIG. 18 , and a flowchart illustrating the method is shown in FIG. 19 .
- the examplar delivery method shown in FIG. 18A involves using an endoscope 1810 to place one or more guidance elements 1880 (for example a needle, a guidewire, and/or a guidance catheter) between the access body lumen (e.g. the duodenum, stomach, or jejunum) and the gallbladder 14 .
- guidance elements 1880 for example a needle, a guidewire, and/or a guidance catheter
- a guidance catheter may be advanced in the patient's gastrointestinal tract, often but not necessarily within the working channel 1812 of an endoscope 1810 , until the distal tip of the guiding catheter is proximal to the desired placement location for the device 1820 .
- a needle may be advanced out of the distal end of the guiding catheter through the wall in the gastrointestinal tract, e.g. at a duodenum 30 , continuing through the wall of the gallbladder 14 , and into the lumen of the gallbladder 14 .
- bile may be aspirated through the needle or any other guidance element 1880 to reduce the pressure within the gallbladder 14 , reducing the risk of bile escaping the gallbladder within the peritoneum.
- the guidance element e.g. needle, guidewire, guidance catheter
- the guidance element may incorporate an aspiration port, either distal or anywhere along a surface or wall.
- a guidewire may be inserted into the gallbladder lumen through the needle. In cases where a guidewire is used, the needle may be withdrawn once the guidewire has been inserted.
- either the guidance catheter or a separate dilatation catheter, having an inflatable balloon 1885 on the distal portion thereof, may be advanced over the previously introduced needle or guidewire until the balloon 1885 is properly positioned through the wall of the gastrointestinal tract and the wall of the gallbladder 14 .
- the dilatation balloon 1885 may be inflated with inflation fluid one or more times to a predetermined size so that the tissue around the puncture site is expanded to accommodate the device 1820 .
- the inflated diameter of the section of the balloon contacting the wall of the gallbladder 14 and gastrointestinal tract access lumen is slightly smaller than the outer diameter of the tubular portion 1830 of the device 1820 that will be inserted through the puncture.
- the device 1820 may then be guided into position over the guidance element(s) 1880 (e.g. needle, guidewire, guidance catheter) through the hole in the wall of the gastrointestinal tract and the wall of the gallbladder 14 to the desired depth. Once in the desired position, the device 1820 may be deployed and held in position by its retaining features 1822 and the adjacent tissue.
- the guidance element(s) 1880 e.g. needle, guidewire, guidance catheter
- the device 1820 When the device 1820 is delivered in conjunction with a guidance element 1880 such as a needle, a guidewire, and/or a guidance catheter, the device 1820 may be positioned within a delivery catheter 1816 that constrains the device 1820 in its delivery configuration ( FIG. 18B ).
- the delivery catheter 1816 may incorporate a separate lumen to accommodate the guidance element 1880 .
- the delivery catheter 1816 When the device 1820 is placed in the desired position, the delivery catheter 1816 may be manipulated or repositioned relative to the device 1820 in order to deploy the device 1820 and effect its reconfiguration into the deployed configuration or the final configuration ( FIGS. 18C-E ).
- Manipulation of the delivery catheter 1816 may, for example, include activation of a deployment device such as a balloon section 1885 ( FIG. 18F ).
- the balloon profile may have a consistent profile, or it may have a varied profile, such as that shown in FIG. 18G .
- a varied balloon 1885 profile may facilitate tissue approximation (e.g. the wall of the gallbladder 14 and the wall of the gastrointestinal tract access lumen such as a duodenum 30 ) during dilatation and delivery steps.
- tissue approximation e.g. the wall of the gallbladder 14 and the wall of the gastrointestinal tract access lumen such as a duodenum 30
- a delivery catheter 1816 may be inserted over the guidance element 1880 and into the gallbladder 14 .
- the delivery catheter 1816 carries the conduit device 1820 and conduit deployment device, such as a balloon section 1885 , which can be expanded to both dilate the tissue and deploy the conduit 1820 into a deployed or final configuration once it is positioned in the desired location ( FIG. 18G-I ).
- conduit deployment device such as a balloon section 1885
- the delivery catheter 1816 and any other delivery elements 1880 may then be withdrawn, leaving the conduit 1820 in place.
- the delivery catheter 1816 may be sized to fit in the working channel 1812 of a typical endoscope 1810 .
- the conduit device's 1820 outer profile may be similar to that of the delivery catheter 1816 , facilitating insertion and reducing the potential to catch or snag anywhere during delivery.
- the conduit 1820 may be deployed and secured in place.
- Another delivery method is to mount either the conduit 2020 or a holder for the conduit on the distal end of an endoscope 2010 . After navigating to the desired location with the endoscope 2010 , the conduit 2020 may then be inserted through the wall of the access body lumen and the gallbladder 14 to form the desired passageway. This is illustrated in FIG. 20 .
- the guidewire could be of a traditional design and used according to conventional methods.
- a length of guidewire is inserted into the gallbladder 14 through the wall of the gallbladder.
- An extra length of guidewire is then inserted and allowed to accumulate within the gallbladder 14 , thus passively retaining the guidewire distal end in the gallbladder 14 while the guidewire is used to deliver additional elements.
- This type of guidewire has no additional feature that serves to retain the distal end within the gallbladder 14 during treatment: the distal end floats freely in the lumen of the gallbladder 14 , and withdrawal involves simply pulling the guidewire from the proximal end.
- An alternate embodiment of the guidewire 2182 includes a retention feature 2118 to retain the distal end once it has been successfully inserted into the gallbladder 14 lumen. This allows for the guidewire 2182 to be placed under increased tension without the risk of pulling it out of the gallbladder 14 unintentionally.
- the ability to place the guidewire 2182 under tension may be useful, for instance, when approximating the walls of the access body lumen and the gallbladder 14 , during the insertion of a delivery catheter (not shown), and delivery and/or deployment of a conduit.
- the feature 2118 on the distal end of a guidewire 2182 that provides for retention may have a number of different shapes, such as a “T” ( FIG. 21A ), an arrow head ( FIG.
- a retention feature may be engaged by first inserting the guidewire 2114 into the gallbladder lumen, then pulling back on the guidewire 2114 until the retention feature engages with the gallbladder wall.
- the guidewire is typically made of Nitinol, however it may be comprised of any material that is capable of elastically bending with the required radii and supporting the required tension in a thin, small profile.
- kits All of the devices required to deliver and install a conduit may be packaged in a kit. Bundling all devices, tools, components, materials, and accessories needed to perform these procedures into a kit may enhance the usability and convenience of the devices, and also improve the safety of the procedure by encouraging clinicians to use the items believed to result in the best outcomes.
- the kit may be single-use or reusable, or it may incorporate some disposable single-use elements and some reusable elements.
- the kit may contain, but is not limited to, the following: implantable and/or non-implantable devices; delivery devices (e.g.
- the kit may be supplied in a tray, which organizes and retains all items so that they can be quickly identified and used.
- cholangitis infection of the common bile duct 18
- This condition is usually bacterial, and occurs when the bile duct is blocked by gallstones 20 or a tumor.
- Traditional treatment involves the insertion a stent or drainage catheter into the common bile duct 18 to allow bile to drain into the duodenum from locations above the obstruction. Placement of a conduit into the gallbladder 14 may allow for an alternate method of draining bile and/or other fluids into the duodenum. Any blockage in the common bile duct 18 between the entrance of the cystic duct and the duodenum may be treated in this way. See FIG. 2 .
- Another use of the devices and techniques described elsewhere in this application may be to create anastomoses between any body lumens in proximity to one another. This may include, but is not limited to: small bowel to small bowel anastomoses, small bowel to large bowel anastomoses, large bowel to large bowel anastomoses, and stomach to small bowel anastomoses. Additionally, creating a conduit between the stomach and other body lumens may be useful and effective for treating and/or managing obesity.
- Another use of the devices and techniques described herein is for drainage of any body lumen into another body lumen in proximity, for example, the drainage of pancreatic pseudocysts.
Abstract
The application discloses devices, systems, kits and methods for treating biliary disease. Device comprise, for example, a component configured for deployment between a gallbladder and location within a gastrointestinal tract of a patient which has a proximal end and a distal end with a lumen extending therethrough. A method of deploying the device can be achieved by, for example, creating a duct or fistula between a gallbladder lumen and a portion of a gastrointestinal tract; and providing for drainage from the gallbladder to the gastrointestinal tract.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/991,682, filed Nov. 30, 2007, and Application No. 61/033,368 filed Mar. 3, 2008, which application is incorporated herein by reference.
- This application has related subject matter to U.S. Utility patent application Ser. No. 12/277,338, filed Nov. 25, 2008, entitled “Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct” by Jacques Van Dam, J. Craig Milroy, and R. Matthew Ohline (identified as Attorney Docket No. 36233-701.203) and U.S. Utility patent application Ser. No. 12/277,443, filed Nov. 25, 2008, entitled, “Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder” by Jacques Van Dam, J. Craig Milroy, and R. Matthew Ohline, which applications are incorporated herein by reference.
- The invention described in this patent application addresses challenges confronted in the treatment of biliary disease. Biliary disease includes conditions affecting the gallbladder, cystic duct, and common bile duct.
- Bile is a greenish-brown digestive fluid produced by the
liver 10 illustrated inFIG. 1 , and is vital for the digestion of fatty foods. Bile is secreted by liver cells and collected by a network of ducts that converge at the commonhepatic duct 12. While a small quantity of bile drains directly into the lumen of the duodenum 30 (the section of small intestine immediately downstream of the stomach), most travels through the commonhepatic duct 12 and accumulates in the lumen of thegallbladder 14. Healthy gallbladders are pear-shaped sacs with a muscular wall that, on average, measure 10 cm in length and can store approximately 50 ml of fluid within its lumen. When fatty foods are ingested, the hormone cholecystokinin is released, which causes thegallbladder 14 to contract. Contraction of thegallbladder 14 forces bile to flow from thegallbladder 14, through thecystic duct 16, into thecommon bile duct 18, out thepapilla 28, and finally into theduodenum 30 of the small intestine. Here, it mixes and reacts with the food that exits the stomach. The Sphincter of Oddi 26 controls secretions from the liver,pancreas 24, andgallbladder 14 into theduodenum 30 of the small intestine. The opening on the inside of the descendingduodenum 30 after the Sphincter of Oddi 26 is called the major duodenal papilla 28 (of Vater). Together, the biliary ducts, thegallbladder 14, thecystic duct 16 and thecommon bile duct 18 comprise the biliary system (FIG. 1 ). - The
pancreas 24 is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland (producing several important hormones, including insulin, glucagon, and somatostatin), as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme. Thepancreatic duct 22, or duct of Wirsung, is a duct joining thepancreas 24 to thecommon bile duct 18 to supply pancreatic juices which aid in digestion provided by the exocrine pancreas. Thepancreatic duct 22 joins thecommon bile duct 18 just prior to themajor duodenal papilla 28, after which both ducts perforate the medial side of the second portion of theduodenum 30 at the major duodenal papilla. - The most common problem that arises in the biliary system is the formation of gallstones, a condition called cholelithiasis. Approximately 20 million Americans have gallstones, and about 1-3% will exhibit symptoms in any given year. In the U.S., gallstones are more common among women, with 25% of women having gallstones by the age of 60 and 50% by the age of 75. Pregnancy and hormone replacement therapy increase the risk of forming gallstones. Prevalence is lower for American men: approximately 25% will develop gallstones by the age of 75. In the U.S., gallstones are responsible for the highest number of hospital admissions due to severe abdominal pain.
-
Gallstones gallbladder 14,cystic duct 16, and/or the common bile duct 18 (FIG. 2 ). By themselves,gallstones 20 do not necessarily result in disease states. This is the case 90% of the time. However, stones can cause infection and inflammation, a condition known as cholecystitis, which is generally the result of restricting or blocking the flow of bile from thegallbladder 14 andcommon bile duct 18, or the fluids secreted by thepancreas 24. - Gallbladder disease may be chronic, and patients who suffer from this may periodically experience biliary colic. Symptoms include pain in the upper right abdomen near the ribcage, nausea, and/or vomiting. The pain may resolve within an hour of onset, may prove unresponsive to over-the-counter medicines, and may not decrease with changes of position or the passage of gas. Recurrence is common, with pain often recurring at the same time of day, but with frequency of less than once per week. Fatty or large meals may cause recurrence several hours after eating, often awakening the patient at night. Patients may elect to suffer from these symptoms for very long periods of time, such as years or even decades.
- Patients with chronic cholecystitis have gallstones and low-grade inflammation. Untreated, the
gallbladder 14 may become scarred and stiff over time, leading to a condition called dysfunctional gallbladder. Patients who have chronic cholecystitis or dysfunctional gallbladder may experience gas, nausea, and abdominal discomfort after meals, and chronic diarrhea. - Acute cholecystitis (a surgical emergency) develops in 1-3% of those with symptomatic gallstone disease, and is due to obstruction of the
common bile duct 18 orcystic duct 16 by stones or sludge. Symptoms are similar to biliary colic, though they are more severe and persistent. Pain in the upper right abdomen can be constant and severe, the intensity may increase when drawing breath, and it may last for days. Pain may radiate to the back, under the breastbone or the shoulder blades, and it may be perceived on the left side of the abdomen. In addition to nausea and vomiting, one third of patients experience fever and chills. Complications from acute cholcystitis can be serious and life threatening, and include gangrene, abscesses, perforation of thegallbladder 14 which can lead to bile peritonitis, pus in the gallbladder wall (empyema), fistulae, and gallstone ilius (when a gallstone creates a blockage in the small intestine). - When
gallstones 20′ become lodged in the common bile duct 18 (FIG. 2 ), the condition is known as choledocholithiasis. Symptoms for this condition include pain, nausea and vomiting, and some patients develop jaundice, have dark urine and/or lighter stools, rapid heartbeat, and experience an abrupt drop in blood pressure. These symptoms can also be accompanied by fever, chills, and/or severe pain in the upper right abdomen. Complications from choledocholithiasis can also be very serious, and include infection of the common bile duct 18 (cholangitis) and inflammation of the pancreas 24 (pancreatitis). - A smaller patient population suffers from gallbladder disease that occurs in the absence of gallstones. This condition, called acalculous gallbladder disease, can also be chronic or acute. Chronic acalculous gallbladder disease, also called biliary dyskinesia, is thought to be caused by motility disorders that affect the gallbladder's ability to store and release bile. Acute acalculous gallbladder disease occurs in patients who suffer from other serious illnesses which can lead to inflammation of the
gallbladder 14 because of a reduction in the supply of blood to thegallbladder 14 or a reduced ability to contract and empty bile into theduodenum 30. - Cancer can also develop in the
gallbladder 14, though this condition is rare. Gallstones have been found in 80% of patients with gallbladder cancer. Gallbladder cancer typically develops from polyps, which are growths inside thegallbladder 14. When polyps 15 mm across or larger are observed, the gallbladder is removed as a preventive measure. Polyps smaller than 10 mm are widely accepted as posing low risk and are not generally removed. When detected early, before the cancer has spread beyond the mucosa (inner lining) of the gallbladder, the 5-year survival rate is approximately 68%. However, gallbladder cancer is not usually detected until patients are symptomatic, by which time the disease is more advanced. - The most effective treatment for biliary disease has been surgical removal of the
gallbladder 14, a procedure called cholecystectomy. Surgical removal of thegallbladder 14 is indicated for patients who experience a number of less severe gallstone attacks, cholecystitis, choledocholithiasis, pancreatitis, acalculous biliary pain with evidence ofimpaired gallbladder 14 emptying, those at high risk for developing gallbladder cancer, and those who have previously undergone endoscopic sphincterotomy for common bile duct stones. Other treatment modalities exist and are frequently used, but gallbladder disease tends to recur in the majority of patients who forgo cholecystectomy and pursue alternatives. Removal of thegallbladder 14 is highly successful at permanently eliminating biliary disease. Cholecystectomy is one of the most commonly performed procedures on women. Thegallbladder 14 is not an essential organ, and after a period of adjustment post surgery, patients tend to return to more or less normal digestive function. - Cholecystectomy can be performed either as open surgery, which requires a single larger incision in the upper right abdomen, or laparoscopic surgery, in which several small instruments are inserted through much smaller incisions in the abdomen. Approximately 80% of cholecystectomies are performed laparoscopically. The primary benefits of this minimally invasive approach are faster recovery for the patient, and a reduction in overall healthcare costs. Patients who receive laparoscopic cholecystectomy are usually released the same day. By contrast, patients receiving open cholecystectomies typically spend 5-7 days in a hospital before release. 5-10% of laparoscopic procedures convert to open procedures when difficulties arise, such as injury to major blood vessels, inadequate access, inadequate visualization, previous endoscopic sphincterotomy, and thickened gallbladder wall. Complications from cholecystectomy (open or laparoscopic) include bile duct injuries (0.1-0.5% for open, 0.3-2% with a declining trend for laparoscopic), pain, fatigue, nausea, vomiting, and infection. In up to 6% of cases, surgeons fail to identify and remove all gallstones present.
- In some cases, the degree of infection and inflammation prevents patients from undergoing immediate cholecystectomy. In these cases, the
gallbladder 14 must be treated with antibiotics and anti-inflammatory agents, and drained through a tube into a reservoir outside the abdomen. Placement of this tube occurs in a procedure called percutaneous cholecystostomy, in which a needle is introduced to thegallbladder 14 through the abdomen, fluid is withdrawn, and a drainage catheter is inserted. This catheter drains into an external bag which must be emptied several times a day until the tube is removed. The drainage catheter may be left in place for up to 8 weeks. In cases where no drainage catheter is inserted, the procedure is called gallbladder aspiration. Since no indwelling catheter is placed, the complication rate for gallbladder aspiration is lower than that of percutaneous cholecystostomy. - Treatment methodologies other than cholecystectomy include expectant management, dissolution therapy, endoscopic retrograde cholangiopanctreatograpy (ERCP) with endoscopic sphincterotomy, and extracorporeal shockwave lithotripsy (ESWL).
- Expectant management is appropriate for patients who have gallstones but no symptoms, and for non-emergency cases with less severe symptoms. This approach is not recommended when patients are in high risk categories (e.g. high risk for gallbladder cancer) or have very large gallstones (e.g. greater than 3 cm).
- Oral dissolution therapy involves the administration of pills containing bile acids that can dissolve gallstones. This approach is only moderately effective, and the rate of recurrence of gallstones after completion of treatment is high. It is not appropriate for patients with acute inflammation or stones in the common bile duct (more serious conditions). Dissolution therapy tends to be more effective for patients with cholesterol stones, and is sometimes used in conjunction with lithotripsy. Despite its relative ineffectiveness, it is costly: treatment can last up to 2 years and the drugs cost thousands of dollars per year.
- Related to oral dissolution therapy is contact dissolution, a procedure that involves injection of a solvent such as methyl tert-butyl ether (MTBE) directly into the
gallbladder 14. This approach is highly effective at dissolving gallstones, but patients may experience severe burning pain. - ERCP (endoscopic retrograde cholangiopancreatography) is a procedure in which an endoscope is introduced through the mouth of a patient, past the stomach to the
papilla 28, where thecommon bile duct 18 empties into theduodenum 30. The overall goal of the procedure is to insert instruments and tools into thecommon bile duct 18 via thepapilla 28 in order to treat biliary disease. Typically, endoscopic sphincterotomy is performed, which is a procedure that enlarges the opening of thepapilla 28 in the small intestine. This can be accomplished surgically or via balloon dilation. Contrast agent is introduced into thecommon bile duct 18 to visualize the biliary tree fluoroscopically. Tools for clearing blockages, such as mechanical lithotripsy devices, can be deployed to crush gallstones and remove the resulting debris. Drainage catheters and stents may also be inserted to facilitate the drainage of bile past obstructions. Complications from this challenging procedure occur at a rate of 5-8%, and include recurrence of stone formation, pancreatitis, infection, bleeding, and perforation. - Extracorporeal shockwave lithotripsy (ESWL) is a technique in which focused, high-energy ultrasound is directed at the
gallbladder 14. The ultrasound waves travel through the soft body tissue and break up the gallstones. The resulting stone fragments are then usually small enough to pass through the bile duct into the small intestine. Oral dissolution therapy is often used in conjunction with ESWL. This treatment is not in common use, as less than 15% of the patient population are good candidates. However, ESWL is used to treat patients who are not candidates for surgery. Complications from ESWL include pain in the gallbladder area, pancreatitis, and failure of the gallstone fragments to pass into the small intestine. - An aspect of the invention is directed to devices for treating biliary disease. Suitable devices comprise: a component configured for deployment between a gallbladder and a location within a gastrointestinal tract of a patient, the component having a proximal end and a distal end and a lumen extending therethrough. The devices can be configured for deployment by an endoscope, a needle, a guidewire, a guidance catheter, and/or a dilatation balloon. Endoscopes can further be adapted to comprise an ultrasound device. A system for treating biliary disease is also contemplated which comprises a device for configuring a duct between a gallbladder and a gastrointestinal tract of a patient having a proximal end and a distal end with a lumen extending therethrough between. In some aspects the devices can be configured to further comprise a delivery mechanism for delivering a substance. Deployment of these devices can, in some instances, cause a conduit to be formed between a gallbladder lumen and a target location within the gastrointestinal tract.
- Another aspect of the invention is directed to a biliary disease treatment device comprising: an implant adapted to be delivered by an endoscope to a gastrointestinal site in proximity to a gallbladder, and further adapted to form a conduit between the gastrointestinal site and the gallbladder. The conduit can, for example, be formed between a lumen of the gallbladder and a target location within the gastrointestinal tract, such as proximal to a duodenum.
- Devices according to any one of the configurations disclosed can be formed from a bioresorbable material. Moreover, the devices can be removable and/or expandable. The devices can also be configurable in one or more configurations selected from a deployment configuration, a delivery configuration and a final configuration. Moreover, the devices can be configured such that a profile of the device changes between said configurations. Additionally, or in the alternative, a cross-sectional area of the device can be variable along a length of the devices. In some configurations a component or implant can be configured such that it has a flareable end, suitable flareable ends include ends that are generally hemispherical. Additionally, components or implants can comprise a configurable retainable feature. In some aspects, components or implants can comprise one or more clips configured to secure the components or implants at one or more positions. In some configurations, one or more fenestrations may be provided. Moreover, the lumen or conduit can be configurable to provide restrictable fluid flow or to provide for a valve, such as a flow-restrictor or one-way valve. Any of the configurations of the device can be constructed such that the device is flexible. The system or device can also be configured to include a generally elongate tube that is adapted and configured to extend into the gastrointestinal tract. Configurations that include an elongate tube can be configured such that the tube is patent at a first end; the patent first end can be for placement adjacent the gallbladder. In still other configurations, the elongate tube is not patent at a second end. Moreover, the tube can be configured such that it has an adjustable length. Additionally, one or more fluid control components can be provided to the designs. Additionally, an enlargeable portion comprising two or more legs can be provided.
- Another aspect of the invention is directed to a kit for treating biliary disease comprising a duct forming component positioned between a gallbladder and a gastrointestinal tract. The kit can comprise any of the devices or systems described herein. Additionally, compounds can be provided for delivery to a tissue. Compounds or materials include, but are not limited to, for example, one or more of each of sclerosing agents, antibiotics, inflammatory agents, anti-inflammatory agents, biocompatible gels, and biocompatible foams. Additionally, a catheter, guidewire, needle, guidance catheter or balloon catheter can be provided. In some aspects, the kit can also include an ablation device. Additional components of the kits include, for example, one or more of each of a pair of scissors, a scalpel, a swab, a syringe, a hemostat, a lubricant, a needle, a snare, an antiseptic, and an anesthetic.
- Yet another aspect of the invention is directed to a method for treating biliary disease. A method of treating biliary disease comprises: (a) creating a duct or fistula between a gallbladder lumen and a portion of a gastrointestinal tract; and (b) providing for drainage from the gallbladder to the gastrointestinal tract. Additionally, the method can comprise the step of delivering a substance to the gallbladder via the duct. Additional method steps include delivering a device to the gallbladder through the duct. Suitable devices to be delivered include one or more of a stent, a drug-coated stent, a catheter, a needle, a guidance catheter, a balloon dilatation catheter and/or a guidewire. In some cases, the step of creating the duct further comprises the step of inserting a device in communication between the gastrointestinal tract and the gallbladder lumen. The step of creating the duct between a gallbladder lumen and a portion of a gastrointestinal tract can further comprise the step of inserting a conduit between the gallbladder lumen and the portion of the biliary system. In some aspects, the method further comprises the step of forming a biological duct in situ from a patient's tissue. As will be appreciated by those skilled in the art, the step of inserting a conduit between the gallbladder lumen and the portion of the gallbladder tract can occur at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time. Moreover the methods can further comprise the step of providing a seal to prevent fluid from leaking into a peritoneum. Additionally the gallbladder can be defunctionalized in situ, such as by delivering a substance or material into a space within the gallbladder. Suitable substances or materials include, but are not limited to, gels and foams. In some instances, the delivered substances can be activated in situ. Additionally, an amount of material can be delivered to fill, or substantially fill, the gallbladder lumen. Additionally, in some instances, the step of defunctionalizing is achieved by one or more of sclerosing or necrotizing a tissue within the gallbladder which can, for example, be achieved by an ablation technique.
- Still another aspect of the invention is directed to a method of delivering a device to treat biliary disease comprising: (a) using an endoscope to place a guidewire between an access lumen in a body and a gallbladder; (b) inserting a delivery catheter over the guidewire and into the gallbladder; (c) delivering a conduit on the catheter; and (d) positioning the conduit between the access lumen in the body and the gallbladder to create a lumen therebetween. The methods can also include the step of forming a biological duct in situ from a patient's tissue. Additionally, the step of positioning the conduit can occur at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time. Some methods can further comprise the step of passively retaining a distal end of the guidewire in the gallbladder while the guidewire is used to deliver additional elements. In some instances, the methods include the step of retaining a distal end of the guidewire within the gallbladder. In some methods, gallstones are removed through the created lumen. In other methods, a substance is delivered to the gallbladder via the created lumen. In some instances, the substance occupies the gallbladder lumen and can be one or more of antibiotics, inflammatory agents, and anti-inflammatory agents. Methods may also include preventing bile from entering the or a gallbladder lumen. Additionally, the gallbladder may be localized via endoscopic ultrasound, in some instances. Moreover, it may be useful to access the gallbladder via the gastrointestinal tract. A suitable location for accessing the gallbladder via the gastrointestinal tract would be to access the gallbladder at a duodenum. With any of the methods it may be desirable to alter and/or remove gallstones. Moreover, other obstructions within the biliary system can also be removed. The delivered conduit can be, for example, one or more of a stent, and a drug-coated stent. In some applications of the methods, biliary disease is treated without removal of the gallbladder. In still other applications of the method, a treatment area is visualized as part of the method. In some methods, the conduit is anchored in place. In still other methods, the conduit is changed from a delivery configuration to a deployment configuration, from a delivery configuration to a final configuration or from a deployment configuration to a final configuration. Still other methods provide for reducing a cross-sectional profile of the conduit, providing a seal to prevent fluid from leaking into a peritoneum, and/or restricting fluid flow from the gallbladder lumen to the gastrointestinal tract. Other methods include operating a valve to restrict fluid flow.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention will be set forth with particularity in any claims presented based on this application. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 illustrates an overview of the biliary system; -
FIG. 2 illustrates the biliary system with gallstones; -
FIG. 3 illustrates an endoscope accessing the biliary system via the intestinal system; -
FIGS. 4A-D illustrate embodiments of a device adapted to provide a conduit between two body lumens; -
FIGS. 5A-B illustrates the outward radial force applied by an embodiment of a device adapted to provide a conduit between two body lumens; -
FIGS. 6A-B illustrates an embodiment of a device with a retaining feature; -
FIGS. 7A-G illustrate variations of retaining features; -
FIGS. 8A-B illustrate another variation of a retaining feature; -
FIGS. 9A-C illustrates a delivery configuration which reduces cross-sectional area; -
FIGS. 10A-B illustrates an alternate embodiment of a device; -
FIG. 11 illustrates an alternate embodiment of a device having an elongate tube; -
FIGS. 12A-C illustrate an alternate embodiment formed from shape memory material; -
FIGS. 13A-G illustrate a close-wound spring embodiment of the device; -
FIGS. 14A-B illustrates a stent-like embodiment; -
FIGS. 15A-B illustrate retaining features; -
FIGS. 16A-E illustrate a variety of valve embodiments; -
FIGS. 17A-B illustrate a variety of plug embodiments; -
FIGS. 18A-I illustrate delivery of a device according to the invention via a catheter; -
FIG. 19 illustrates the steps of delivering a device according to the invention via a catheter; -
FIG. 20 illustrates delivery of a device according to the invention at the distal tip of an endoscope; and -
FIGS. 21A-H illustrate a guidewire retention feature. - Devices, systems, methods and kits provided herewith can obviate the need for a plurality of procedures, including, for example: 1) percutaneous cholecystostomy, 2) cholecystectomy, 3) percutaneous trans-hepatic cholangiography (PTHC), and 4) endoscopic retrograde cholangiopancreatography (ERCP). Additionally, disclosed treatment modalities enable treatment of a distal
common bile duct 18 obstruction, e.g. secondary to pancreatic carcinoma, cholagiocarcinoma, and/or ampullary carcinoma. As will be appreciated by those skilled in the art, the conventional standard of care for treating biliary disease has been surgical removal of thegallbladder 14 and closure of thecystic duct 16. While this has proven to be an effective mechanism for permanently eliminating biliary disease and its recurrence, the present invention seeks to accomplish the same end in a less invasive and less costly way. This may be achieved by treating biliary disease without requiring the removal of thegallbladder 14. Methods and apparatus are described in this application that are intended to effectively treat biliary disease with thegallbladder 14 andcystic duct 16 left in situ by providing a shunt to the gallbladder. - A method of treating biliary disease involves using an
endoscope 310 to access aregion 350 in the gastrointestinal (GI) tract (FIG. 3 ) to which thegallbladder 14 is in close proximity, locating thegallbladder 14, accessing thegallbladder 14, and then treating the underlying condition that led to the need for intervention (FIG. 3 ). Treatments may also include, but are not limited to: providing for drainage of thegallbladder 14 and/or the biliary tree, delivering suitable materials or substances, such as antibiotics, inflammatory, anti-inflammatory agents (any of which may be short-term acting, fast acting, or time release), and/or other substances (e.g. adhesives, bioadhesives, etc.) to thegallbladder 14 and/or biliary tree, removinggallstones 20, facilitating the destruction and subsequent removal of gallstones, clearing obstructions, delivering catheters, delivering stents (drug coated or not drug coated), temporarily or permanently defunctionalizing thecystic duct 16, temporarily or permanently defunctionalizing thegallbladder 14. Devices and therapies can be delivered in a single treatment, with minimal likelihood of or necessity for follow-up or repeat procedures. - The gallbladder can be accessed by any suitable mechanism or procedure including, percutaneously, endoscopically, laparascopically, and the like. Moreover, any of the materials and substances delivered to the gallbladder can be delivered concurrently or sequentially. Delivery of substances can occur sequentially in time or the sequence of delivery can be separated by seconds, minutes, or hours.
- Localization of the
gallbladder 14 can be performed via endoscopic ultrasound (EUS) by accessing the wall of the GI tract with anendoscope 310 as shown inFIG. 3 . Localization may also be achieved by any other method that visualizes anatomical features, such as fluoroscopy, x-rays, magnetic resonance imaging (MRI), computed axial tomography (CT) scans, ultrasound imaging from outside the body, or any method of anatomical imaging and visualization. - Once the
gallbladder 14 has been located, it may be accessed and/or treated 350 through the wall of the GI tract (or any lumen in proximity to the gallbladder 14) with tools and devices (e.g. needles, guidewires, guidance catheters, dilators, etc.) delivered through, for example, anendoscope 310. Such tools and devices may be inserted down the length of the endoscope's workingchannel 312, or loaded onto or near the distal end of theendoscope 310. Alternately, tools and other devices may be used that do not require the aid of the endoscope for navigation or delivery. Direct visualization may be provided by theendoscope 310 during the procedure, as well as irrigation, suction, and insufflation. - Though the preferred location for accessing the gallbladder lumen is the duodenum 30, it may also be readily achieved through the wall of other regions of the GI tract, such as the stomach or the jejunum, for example. Thus, any lumen in close proximity to the
gallbladder 14 is a candidate for access to and treatment of thegallbladder 14 and other members of the biliary system. - In the present invention, in situ treatment of the
gallbladder 14 is enabled via the creation of a passageway between the gallbladder lumen and a lumen in close proximity, e.g. at or near the duodenum. This passageway or duct may be created by animplantable device 420, such as those illustrated inFIG. 4 . - The passageway may be temporary or permanent. It may be thought of as a fistula that is intentionally created between the
gallbladder 14 and another lumen in proximity, as described above. Alternately, it may be thought of as a stoma between thegallbladder 14 and another lumen in proximity. The passageway serves as a conduit, an access port, through which a number of actions may be accomplished, drainage may be achieved, and treatments may be delivered. - A
device 420 forming the passageway may be left in the patient for a short period of time, such as a few hours, a few days or a few weeks, or it may be left in place for extended periods of time, such as several weeks, months, or years. Thedevice 420 may also be left in place permanently. If it is left in place long-term, tissue may form around thedevice 420, creating a fistula that connects thegallbladder 14 to the access lumen which may persist even if thepassageway device 420 is removed, thus forming a biological insitu device 420 from the patient's own tissue. The fistula may be beneficial and useful, as it may continue to allow drainage for the contents of thegallbladder 14 into the small intestine. It may provide either the primary or a secondary mechanism for delivering bile into the digestive system, for example. It may also provide convenient access in cases where repeated treatments are required. Though there may be no need to close the resulting fistula, it may also be closed at any time by a clinician should this become desirable. After removal of adevice 420 that initially formed the passageway, a fistula may remain open for a period of time and then close on its own, and may pose no additional risk and prove to be an acceptable course of events. Whether thedevice 420 is left in place or removed, and whether the fistula is left open or closed, evidence at the site may serve to mark the location of treatment in the event of future procedures. - To facilitate delivery and deployment of a
device 420, it may be useful to reconfigure its shape. For example, the cross-sectional area presented by thedevice 420 at various locations may be reduced, thus, for example, reducing its overall profile. In cases where the configuration of thedevice 420 is caused to change, it may be helpful to conceive of thedevice 420 having one or more configurations, for example: one configuration when it is delivered (a “delivery configuration”), another configuration when it is deployed (a “deployment configuration”), and yet another configuration when it is in place and functional (a “final configuration”). Still other configurations may also be necessary or useful. For the delivery configuration, it may be advantageous to alter (e.g. reduce) the cross-sectional area or profile, so that it more easily fits delivery mechanisms, such as the working channel of an endoscope 310 (illustrated inFIG. 3 ). During deployment, the configuration of thedevice 420 may be altered so that placement into the patient is facilitated. This may be different from both the delivery configuration and the final configuration, though this is not necessarily the case. As will be appreciated by those skilled in the art, one or more configurations can be the same or substantially the same. - The preferred embodiment of the conduit is that of a short tube that is flared into hemispherical bowl-like shapes at both ends, as depicted in
FIG. 4 . The flared bowl-like shapes at thedistal end 422 and theproximal end 425 secure theconduit device 420 in the desired location within thegallbladder 14 and the access lumen, e.g. theduodenum 30. Theconduit 420 forms the proposedpassageway 424 between thegallbladder 14 and the body lumen from which it will be accessed, such as through theduodenum 30. Thetubular portion 430 of theconduit 420 is typically about 4-10 mm in length h1, with an inner diameter w1 of the device lumen orpassageway 424 large enough to facilitate drainage and access, typically in the range of 2-10 mm. However, other dimensions can be used without departing from the scope of the invention. The outer diameter of thetubular portion 430 of theconduit 420 is typically larger than about 3 mm (10 French) in its final configuration. A variation of the preferred embodiment, depicted inFIG. 4B , comprises a short tube which is bent at an angle, rather than straight, which may beneficially accommodate anatomical variations. Another variation of the preferred embodiment, depicted inFIG. 4C , comprises a longer tube which may allow for relative motion between the gallbladder and the connected lumen, while maintaining patency of the conduit. This configuration may optionally include additional retaining features: a first 415 which is proximal to thedistal retaining feature 422 and a second 419 which is distal to theproximal retaining feature 425. These additional retaining features serve to secure the tissue of the gallbladder wall and the connected lumen (e.g. the wall of the duodenum) and prevent leaks even as the structures undergo relative motion.FIG. 4D shows another variation in which the tube comprises a series of loops so that the distance h1 between thedistal retaining feature 422 and theproximal retaining feature 425 may change without applying excessive force to the tissue adjacent to the anchors. As shown inFIG. 5 , thetubular portion 530 may have radial compliance so that it presses gently but positively outward against the tissue it penetrates. When the original hole in the lumens' walls is smaller than the diameter of the conduit'stubular portion 530 in its final configuration, the tissue will squeeze down around thedevice 520 as thetube 530 generates outward radial force F. This will facilitate sealing, and prevent bile and/or other fluids from leaking into the peritoneum. The flared features 422 and 425, as illustrated inFIG. 4 serve to secure theconduit 520 in place, as well as provide slight tension to approximate thegallbladder 14 wall to the wall of the body lumen providing access. The soft and compliant nature of the preferred materials also provide for a measure of relative motion between thegallbladder 14 and connected lumen, which may increase the comfort of the patient. These retaining features 422 and 425 at either end of thedevice 420, as illustrated inFIG. 4 , have preferred dimensions of approximately 25 mm diameter at their widest point w2, and are approximately hemispherical in shape so that their effective height h2 is approximately 12.5 mm. They may be co-molded or made as one piece together with thetubular portion 430. - A variation on this embodiment includes an
integral retaining feature 622 on one end of the device'stubular portion 630, but does not include it on the opposing end as shown inFIG. 6 . In this configuration, theintegral retaining feature 622 is compressed down to a minimal profile for delivery, and then allowed to expand outward during deployment. Once thedevice 620 is in the desired location, a retainingclip 628 may be added over the end of thetube 630 that has no integral retaining feature. The retainingclip 628 may have a single location on thetube 630 where it is securable, or it may be adjustable so that theclip 628 may be secured in a variety oflocations 631. This provides for adjustability of the compression applied to the walls of the body lumens approximated by the conduit 620 (the gallbladder wall and the wall of the adjacent lumen, such as at or near the duodenum 30). - The retaining
feature 422 and 425 (FIG. 4 ) located at either one end (as illustrated inFIG. 6 ) or both ends (as illustrated inFIG. 4 ) of thetubular portion 430 of thedevice 420 may be embodied in a number of different shapes. The hemispherical flared retainingfeature 422 provides a measure of separation between the entry of thetubular portion 430 of theconduit 420 and the body lumen in which it resides. This may be useful in cases where it is undesirable for the contents of the body lumen to enter theconduit 420 directly (e.g. inside theduodenum 30, it may be undesirable for partially digested food to enter the conduit 420). When this bowl shaped retainingfeature 422 is suspended upside down or sideways, it is especially effective at preventing ingress of undesirable matter. However, other configurations that provide less separation between theconduit 420 and the body lumen may be useful. Other designs may allow for less restricted flow of fluid from within a body lumen into the lumen of theconduit 420. This may be useful, for example, inside thegallbladder 14, where complete drainage of bile may be beneficial. An alternate embodiment based on the previously-described hemispherical shape is that of abowl 722 with slots 732 (FIG. 7A ). Another embodiment is ahemispherical shape 722 that has apertures or holes 734 incorporated into it so that it is fenestrated (FIG. 7B ). The incorporation of fenestrations may be applied to any shape to allow for flow, e.g. globes, tubes, etc. - Shapes other than hemispherical bowls may also have useful properties. One such embodiment is that of a flat, or nearly flat, plate as an
anchoring feature 722. This is illustrated in FIG. 7C(1). One advantage of this flat or nearly flat shape is that most or all of the fluid inside the lumen where it resides (e.g. the gallbladder 14) may pass into theconduit 720, and there will be little or no void or dead space where fluids may pool and fail to flow. The edges of a flat or nearly flat retaining feature may be rounded or curled up slightly in order to prevent trauma to adjacent tissue, FIG. 7C(2). Another variation of the shape of the anchoring or retainingfeature 722 is configured so that it resembles lines of longitude of a globe, as shown inFIG. 7D . In this configuration, at least twolegs legs 738 may be incorporated, with the semicircles joined at the base 721 (the connection to the tube) and the apex 723 (the location farthest from the tube). In order to reconfigure this design to have a small cross-sectional area, which may be useful for delivery, the apex 721 may be pushed away from thetube 730, which will collapse the globe shaped retainingfeature 722 into a linear configuration. This may be achieved with the use of a wire (not shown) or any other element which may push the apex 721 away from thetube 730. Another embodiment of the retainingfeature 722 at the end(s) of the conduit's tubular portion resembles the shape and organization of a flower'spetals 740. Thepetals 740 are joined at the point where they contact the tube 730 (similar to the flower's stem), and spread outwards when unconstrained, as shown inFIG. 7E . These may also be reconfigured in order to reduce the cross-sectional area, which may be useful during delivery of thedevice 720, and then caused to spread outwards once thedevice 720 is delivered and in a suitable orientation for its final configuration. Another embodiment of adevice 720 has a retainingfeature 722 that resembles the extensible portions of a drywall anchor or toggle, as shown inFIG. 7F . In this configuration, the retaining feature's default (unconstrained) configuration is fully extended, so that the cross-sectional area is reduced. When desired, e.g. after delivery or during deployment, theapex 723 of the extensible portions of the retaining feature may be drawn in towards thetubular portion 730 of theconduit 720, spreading out a set oflegs 738 in the process. The apex 723 may be drawn in by pulling on a wire (not shown), for example, or any other element adaptable to apply tension at the apex 723. Alternately, the retaining feature's default (unconstrained) configuration may be fully contracted, so that the cross-sectional area is maximized. In this case, a wire or similar element may be used to push the apex 723 away from thetubular portion 730 of theconduit 720 to reduce the cross-sectional area for delivery. - In yet another embodiment of a device according to the invention, a retaining
feature 722 has an increase in the outer diameter of thetube 730 comprising the conduit 720 (FIG. 7G ). This embodiment may be configured to have a consistent outer diameter during delivery and deployment, and then configured to have an increased outer diameter for itsfinal configuration 722, which serves to secure theconduit 720 within the body lumen. - In still another embodiment of a retaining
feature 822, thedevice 820 is shaped in such a way that it may be pushed through a wall of a body lumen or lumens directly, and then rotated into position along with theconduit 820, to secure the two body lumens together and hold theconduit 820 in place, as illustrated inFIG. 8A . As illustrated inFIG. 8B , the retaining feature in this embodiment may be divided into more than oneelement elements 822′, 825′ may be rotated radially to better secure theconduit 820 once it is in position. As shown, pairs ofelements conduit 820 in place, however any number ofelements - As shown in
FIG. 9A , a method for altering the configuration of thedevice 920 to facilitate delivery is to elongate thedevice 920. If thedevice 920 is sufficiently elongated, the cross-sectional area will be reduced, in some cases substantially. Once thedevice 920 has been elongated and its cross-sectional area reduced, it may be loaded into a sheath, capsule, or other dimensional retaining component 942 so that this low profile configuration is maintained until it is desirable to alter the configuration, such as when thedevice 920 is deployed or delivered in situ. Alternately, thedevice 920 may be compressed or elongated and then constrained by tightly wrapping or tying it with string or wire. Suitable materials for these techniques include, but are not limited to, shape memory alloys (SMA) such as Nitinol®, and cross-linked polyethylene. Another means of altering the configuration of thedevice 920 to facilitate delivery is to construct it so that its initial shape is that of a series of loops resembling a corkscrew,FIG. 9B . The device may be straightened and then constrained for delivery, or it may be rotated into the preferred position once the distal end has been inserted through the walls of the lumens. This configuration may incorporate at least one loop (FIG. 9C ), and tissue may be retained and constrained between any twoadjacent loops - The conduit may be made of any suitable biocompatible material that is elastic and soft. Silicone is the preferred material. Other materials may optionally be used, e.g. polytetrafluoroethylene (PTFE), expanded PTFE, other members of the fluoropolymer family, urethanes, polyurethanes, and others. The materials can, for example, be soft at body temperature, with durometer typically in the range of 20-60 A. Softer materials are easier to deliver and reduce the risk of injury to adjacent tissue. A suitable material is, for example, soft enough to compress to a compact size for delivery and deployment.
- Embodiments of retaining
features conduit gallbladder 14 and theduodenum 30. Alternately, the retaining features 722, 822 may be formed from less compliant material or a metal (e.g. Nitinol or stainless steel). The retaining features 722, 822 may be formed integrally with other elements of theoverall conduit device 820, such that the components are formed to act in a unified manner by formation as a single component, or may be separate from the other elements of theoverall conduit device 820. The retaining features 722, 822 may be incorporated into the overall assembly during manufacturing, or the parts may be installed by a clinician user prior to use in a patient or during deployment of thedevice 820 within a patient. - The
device 820, or other devices described herein, may also be comprised of a biodegradable, bioabsorbable, or resorbable material, in which case it may dissolve within the mammalian body within a desirable and useful length of time. This could eliminate the need for follow-up procedures to remove thedevice 820 at the end of a course of treatment. Manufacturing thedevice 820 from such a material may not prevent clinicians from actively removing it if the need arose, however. Rather, it would prevent the need to actively remove it in cases where no other treatment was required. - The
conduit 1020 may be comprised of a single component and a single material, or it may be an assembly of different components, some of which may be of different materials that are integrally formed to act or perform in a unified manner once deployed. For instance, aconduit 1020 may be comprised of anSMA spring form 1052, over which silicone 1054 (or another suitable polymer material) is molded as illustrated inFIG. 10 . Thespring form 1052 serves to lend the conduit structure and dimensional stability, while the silicone (or other polymer)outer shell 1054 creates soft surfaces which are unlikely to cause injury to tissue and facilitate sealing of thedevice 1020 in situ and prevent leaks. If SMA materials are used, their transition temperatures can be selected to be slightly below body temperature, so that they can be designed to hold one shape for delivery and deployment, and, after transitioning, they will have the desired shape(s) for optimizing the function of the conduit. Alternately, the SMA material may be used in its superelastic state. - As shown in
FIG. 11 , an alternate embodiment of theconduit device 1120 is formed from an elongate tube 1130 which incorporates aretaining feature 1122 to secure a distal end 1102 (the end within the lumen of the gallbladder 14), adistal end 1102 with sufficient structure to maintain the conduit tube's 1130 patency, aproximal end 1104 that may lack sufficient structure to maintain the conduit tube's patency, and/or an overall length L1 sufficient to deliver bile from thegallbladder 14 into the duodenum 30 a length downstream of the location that theduodenum 30 and thegallbladder 14 are connected by theconduit 1120. If theconduit 1120 is configured so that patency of theproximal end 1104 is not maintained, the tube 1130 may be thought of as highly flexible so that it may be easily moved and/or deformed by materials such aschyme 1139 moving through the small intestine. Downstream delivery of bile into the duodenum 30 may be desirable to prevent bile reflux, a condition that occurs when bile enters the patient's stomach and/or esophagus. For such an embodiment, the length of the tube 1130 may be adjustable. For example, the conduit may be placed into thegallbladder 14 and then trimmed to the desired length. Alternatively, theconduit 1120 may be made available to clinicians in a variety of lengths. - Another alternate embodiment of the
conduit device 1220 as illustrated inFIG. 12A , is comprised entirely of SMA, such as Nitinol. In this embodiment, the radial dimensions of the conduit'stubular portion 1230 may be reducible to facilitate delivery. Methods of achieving this include, but are not limited to: cutting the tube wall parallel to its central axis x and rolling the material tightly to reduce the diameter d for delivery, then expanding it to a greater diameter D and rejoining the edges to form a complete and sealed tubular structure at deployment; simply folding or radially collapsing thetube 1230 to a smaller outer diameter d1 which may be the minimum possible radial dimension from which the SMA material can fully recover its desired tubular diameter d2 and shape at deployment (FIG. 12B ); forming thetube 1230 into a polygon which, in its collapsed configuration folds in an “asterisk” pattern to present minimal cross-sectional area with diameter d1, and in its expanded configuration is a polygon approximating a circular cross-section with diameter d2 (FIG. 12C ). For the configuration depicted inFIG. 12C , the number of sides of the polygon can vary, with higher numbers of sides resulting in beneficial characteristics such as thedevice 1220 more closely approximating a circular cross-section when expanded and collapsing to smaller sizes to facilitate delivery and deployment. - Turning now to
FIG. 13 , an alternate embodiment is depicted that may be comprised entirely of SMA or other material is that of a close-wound spring. Thespring 1352 may be formed by tightly coiling a wire-shaped material, such as Nitinol, other SMA material, stainless steel, titanium, or other suitable material so that it forms a coil as shown inFIG. 13A . Thiscoil 1352 shares characteristics with an extension spring: if tension is applied at the ends of the component, the coils are caused to separate, and this results in the spring creating a compressive return force F. When no external tension is applied to the coil, the gaps between the individual winds of the coil are minimal, and these gaps may be maintained by residual compressive forces imparted to the material during manufacturing as shown inFIG. 13B . To configure such an embodiment for delivery, a tensile load F may be applied, and/or the proximal and distal ends of the spring may be rotated relative to each other T, greatly increasing the length of thedevice 1320, decreasing the cross-sectional area and diameter d accordingly as shown inFIG. 13C . Once thedevice 1320 is in the desired configuration for delivery, it may be loaded into a sheath or other retaining component as shown inFIG. 13D so the configuration is maintained until it is desirable to alter the configuration, such as when thedevice 1320 is deployed. A variation of this embodiment includes acoating 1354 of the material comprising thespring 1352 with a soft, easily deformable polymeric material, such as (but not limited to) silicone, PTFE, or EPTFE as illustrated inFIG. 13E . This could also be achieved by overmolding the polymeric material onto the spring. Thiscoated spring device 1320 has the characteristics described above, as well as the advantages of a soft, compliant, sealed surface: e.g. the potential for bile leaks is reduced (as well as other fluids), and a reduction of the likelihood of injury to surrounding tissue by thedevice 1320 or the acts of delivering and deploying thedevice 1320. Alternately, thespring 1352 could be located outside the soft,compliant material 1354, as illustrated inFIG. 13F , or inside, as illustrated inFIG. 13G . - In another embodiment, the structure of the conduit's
tubular portion 1430 may be comprised of SMA (such as Nitinol or other suitable material) or non-SMA material (e.g. stainless steel or polymeric material) in the form of a stent as shown inFIG. 14 . Thestent 1420 may be covered or may cover another material (such as silicone or EPTFE, as described above) so that it provides a sealed passageway between thegallbladder 14 and the connected body lumen. During delivery, thestent 1420 presents a very small cross-sectional area with initial outer diameter d. During deployment, thestent 1420 is caused to expand outwards against the hole in the walls of the body lumens it connects together. This outwards, radial force of thedevice 1420 and increase in outer diameter D may be optimized in such a way as to reduce the risk of leaks between thegallbladder 14, the connected body lumen, and the surrounding anatomy. - Leaks may also be prevented by coating the external surfaces of any conduit design with a suitable adhesive, such as one that is biocompatible. Such an adhesive serves to bond the
device 1420 to the tissue it contacts, and prevents gaps which may otherwise allow fluid to escape from either lumen or the conduit itself. - The conduit's retaining features 1522 located at either end may also be comprised of SMA (e.g. Nitinol) or other suitable non-polymeric material. This may be the case whether the
tubular portion 1530 of theconduit 1520 is formed from the same or from different materials. Such retaining features may take on a number of shapes and configurations.FIG. 15A shows one embodiment in which the retaining features 1522 resemblespring form fingers 1558, spread out in a flared pattern from the ends of the conduit's tubular portion. During delivery, thefingers 1558 are compressed in towards the central axis x of thetube 1530 to reduce the profile. Upon deployment, thefingers 1558 are allowed to spread outwards to function as aretaining feature 1522.FIG. 15B andFIG. 15C show other embodiments in which theretaining feature 1522 comprises anelement 1558 in a spiral configuration that resembles a corkscrew, with a variable outer diameter. During delivery, this spiral is compressed to reduce its profile, and upon delivery it is caused to expand outwards to serve the purpose of retention. - To ensure that material is only allowed to travel through the conduit from the
gallbladder 14 into the lumen connected via the conduit, e.g., the duodenum, and not in the reverse direction, avalve 1660 may be incorporated into or attach onto theconduit device 1620. For instance, it may be desirable to deliver bile into the digestive tract, and to drain pus or other fluids, but undesirable for partially digested food to move from the small intestine into thegallbladder 14. A valve may be used to prevent flow into thegallbladder 14 from sources other than the biliary system. This is illustrated inFIG. 16 . Among the purposes of the valve 1660: allow the movement of material from thegallbladder 14 into the body lumen (e.g. a duodenum 30) connected by theconduit 1620, prevent flow in the reverse direction, and control the level of pressure that is allowed to develop within thegallbladder 14. Controlling the pressure within thegallbladder 14, and ensuring that the pressure differential between thegallbladder 14 and the connected body lumen remains low, reduces the risk of the bladder's contents (e.g. bile) leaking into the peritoneum. Bile leaks can result in bile peritonitis. Thevalve 1660 may be incorporated or added at any location within the conduit, from the most distal end (the farthest end inside the gallbladder 14) to the most proximal end (the closest end inside the connected lumen), as shown inFIG. 16A . The valve may be made of any suitable material, such as the materials used to construct the conduit. The preferred material for this purpose is silicone. However, it may also be made of any other suitably biocompatible compliant material (in cases where bending characteristics of the material are used to create the flow control feature) or non-compliant material such as stainless steel, nickel-titanium alloy, or titanium (in cases where mechanical elements are used to create the flow control feature). The preferred embodiment is that of a duckbill valve illustrated inFIG. 16B , with a slit in a cone-shaped compliant material that supplies elastic forces that cause it to be closed under normal circumstances, open when the pressure in thegallbladder 14 exceeds the pressure in the connected lumen (e.g. during contraction of the gallbladder 14) by a desired amount, and closed if the pressure in the connected lumen is higher than the pressure in the gallbladder 14 (a condition that might otherwise result in flow in the undesirable direction). In an alternate embodiment, the valve may be designed as a sprung flap (FIG. 16C ), with functional characteristics similar to those of the duckbill valve described above. Another embodiment is that of a bicuspid valve (FIG. 16D ) or tricuspid valve (FIG. 16E ), which also exhibit the characteristics of allowing flow from thegallbladder 14 into the connected body lumen, but not in the reverse direction. Each of these embodiments, and other valve embodiments not specifically described herein, share the flow control characteristics of a) allowing flow from thegallbladder 14 into the body lumen connected through theconduit 1620 when the pressure in thegallbladder 14 is greater than the pressure in the connected lumen by a desired amount, b) not allowing flow from the connected lumen into thegallbladder 14 when the pressure in the lumen exceeds the pressure in thegallbladder 14, and c) not allowing flow between thegallbladder 14 and the connected lumen when little or no pressure differential exists between the two bodies. - An
adjustable valve 1660 may also be incorporated into or added to aconduit 1620. Such a valve would enable practitioners or patients to adjust the difference in pressure between thegallbladder 14 and the connected lumen (such as the duodenum) at which the valve opens. Adjustability may be incorporated into the valve body in such a way that a clinician may adjust it endoscopically, or it may be incorporated in such a way that a clinician or the patient may adjust the valve without requiring additional endoscopy or invasive procedure. - Another approach to controlling flow between the
gallbladder 14 and a connected body lumen is to incorporate or allow for the installation of a blocking mechanism or plug to close off the conduit. This may be in addition to, instead of, or interchangeable with avalve 1660, as described above. The plug may allow for temporary or permanent blockage of the passageway between thegallbladder 14 and the connected body lumen created by the conduit. One embodiment of such a plug is as adiaphragm 1770 or membrane (FIG. 17A ) that allows for short term access to thegallbladder 14 through the conduit by puncturing the material at the center of the block. This may be accomplished, for example, with a needle or fine catheter. The material of the diaphragm or membrane may be selected so that it is self-healing, and as such is re-sealable. This may allow for multiple instances of puncture and hence able to be used for repeated access. Another embodiment of such aplug 1770 is that it is installable, removable and/or replaceable (FIG. 17B ). These functions may be performed endoscopically. - In some aspects it may be desirable to deliver one or more materials, such as fluids or gases, to the interior of the gallbladder lumen either before or after delivery of any of the devices disclosed herein. Moreover, any of the materials and substances delivered to the gallbladder can be delivered concurrently or sequentially. Delivery of substances can occur sequentially in time or the sequence of delivery can be separated by seconds, minutes, or hours.
- An amount of fluid, gas, or material delivered as described throughout can be such that it fills the gallbladder, substantially fills the gallbladder (e.g., fills more than 50% of the gallbladder, more than 75% of the gallbladder, more than 85% of the gallbladder, more than 90% of the gallbladder, more than 95% of the gallbladder, or more than 99% of the gallbladder) or is activatable to fill or substantially fill the gallbladder. Alternatively, in some instances, e.g., the amount of fluid, gas, or material delivered as described throughout can be such that it coats the interior lumen of the gallbladder, or substantially coats the interior lumen of the gallbladder (e.g., coats more than 50% of the gallbladder, more than 75% of the gallbladder, more than 85% of the gallbladder, more than 90% of the gallbladder, more than 95% of the gallbladder, or more than 99% of the gallbladder).
- Delivery of the conduit may be accomplished in a variety of ways. An examplar delivery method is shown in
FIG. 18 , and a flowchart illustrating the method is shown inFIG. 19 . The examplar delivery method shown inFIG. 18A involves using anendoscope 1810 to place one or more guidance elements 1880 (for example a needle, a guidewire, and/or a guidance catheter) between the access body lumen (e.g. the duodenum, stomach, or jejunum) and thegallbladder 14. In cases where a needle, a guidewire and/or a guidance catheter are used, a guidance catheter may be advanced in the patient's gastrointestinal tract, often but not necessarily within the workingchannel 1812 of anendoscope 1810, until the distal tip of the guiding catheter is proximal to the desired placement location for thedevice 1820. A needle may be advanced out of the distal end of the guiding catheter through the wall in the gastrointestinal tract, e.g. at a duodenum 30, continuing through the wall of thegallbladder 14, and into the lumen of thegallbladder 14. As an optional step, bile may be aspirated through the needle or anyother guidance element 1880 to reduce the pressure within thegallbladder 14, reducing the risk of bile escaping the gallbladder within the peritoneum. To facilitate this, the guidance element (e.g. needle, guidewire, guidance catheter) may incorporate an aspiration port, either distal or anywhere along a surface or wall. As another optional step, a guidewire may be inserted into the gallbladder lumen through the needle. In cases where a guidewire is used, the needle may be withdrawn once the guidewire has been inserted. When desirable, either the guidance catheter or a separate dilatation catheter, having aninflatable balloon 1885 on the distal portion thereof, may be advanced over the previously introduced needle or guidewire until theballoon 1885 is properly positioned through the wall of the gastrointestinal tract and the wall of thegallbladder 14. Once in the desired position, thedilatation balloon 1885 may be inflated with inflation fluid one or more times to a predetermined size so that the tissue around the puncture site is expanded to accommodate thedevice 1820. Generally, the inflated diameter of the section of the balloon contacting the wall of thegallbladder 14 and gastrointestinal tract access lumen is slightly smaller than the outer diameter of thetubular portion 1830 of thedevice 1820 that will be inserted through the puncture. In one approach, thedevice 1820 may then be guided into position over the guidance element(s) 1880 (e.g. needle, guidewire, guidance catheter) through the hole in the wall of the gastrointestinal tract and the wall of thegallbladder 14 to the desired depth. Once in the desired position, thedevice 1820 may be deployed and held in position by its retaining features 1822 and the adjacent tissue. - When the
device 1820 is delivered in conjunction with aguidance element 1880 such as a needle, a guidewire, and/or a guidance catheter, thedevice 1820 may be positioned within adelivery catheter 1816 that constrains thedevice 1820 in its delivery configuration (FIG. 18B ). Thedelivery catheter 1816 may incorporate a separate lumen to accommodate theguidance element 1880. When thedevice 1820 is placed in the desired position, thedelivery catheter 1816 may be manipulated or repositioned relative to thedevice 1820 in order to deploy thedevice 1820 and effect its reconfiguration into the deployed configuration or the final configuration (FIGS. 18C-E ). Manipulation of thedelivery catheter 1816 may, for example, include activation of a deployment device such as a balloon section 1885 (FIG. 18F ). The balloon profile may have a consistent profile, or it may have a varied profile, such as that shown inFIG. 18G . Avaried balloon 1885 profile may facilitate tissue approximation (e.g. the wall of thegallbladder 14 and the wall of the gastrointestinal tract access lumen such as a duodenum 30) during dilatation and delivery steps. As described above, it may be desirable for the pilot hole for theguide element 1880 to have a small diameter relative to the size of theconduit device 1820 to be installed, in order to create a better seal between the surfaces and reduce the risk of leaks. Once the guidance element 1880 (e.g. a guidewire) is in place, adelivery catheter 1816 may be inserted over theguidance element 1880 and into thegallbladder 14. Thedelivery catheter 1816 carries theconduit device 1820 and conduit deployment device, such as aballoon section 1885, which can be expanded to both dilate the tissue and deploy theconduit 1820 into a deployed or final configuration once it is positioned in the desired location (FIG. 18G-I ). Once theconduit 1820 has been deployed, thedelivery catheter 1816 and any other delivery elements 1880 (e.g. needle, guidewire, etc.) may then be withdrawn, leaving theconduit 1820 in place. Thedelivery catheter 1816 may be sized to fit in the workingchannel 1812 of atypical endoscope 1810. When resident on or in thedelivery catheter 1816 prior to deployment, the conduit device's 1820 outer profile may be similar to that of thedelivery catheter 1816, facilitating insertion and reducing the potential to catch or snag anywhere during delivery. When theconduit 1820 has been placed properly and connects thegallbladder 14 and the access body lumen, theconduit 1820 may be deployed and secured in place. - Another delivery method is to mount either the conduit 2020 or a holder for the conduit on the distal end of an
endoscope 2010. After navigating to the desired location with theendoscope 2010, the conduit 2020 may then be inserted through the wall of the access body lumen and thegallbladder 14 to form the desired passageway. This is illustrated inFIG. 20 . - For delivery methods that involve the use of a guidewire, the guidewire could be of a traditional design and used according to conventional methods. In this case, a length of guidewire is inserted into the
gallbladder 14 through the wall of the gallbladder. An extra length of guidewire is then inserted and allowed to accumulate within thegallbladder 14, thus passively retaining the guidewire distal end in thegallbladder 14 while the guidewire is used to deliver additional elements. This type of guidewire has no additional feature that serves to retain the distal end within thegallbladder 14 during treatment: the distal end floats freely in the lumen of thegallbladder 14, and withdrawal involves simply pulling the guidewire from the proximal end. - An alternate embodiment of the
guidewire 2182 includes aretention feature 2118 to retain the distal end once it has been successfully inserted into thegallbladder 14 lumen. This allows for theguidewire 2182 to be placed under increased tension without the risk of pulling it out of thegallbladder 14 unintentionally. The ability to place theguidewire 2182 under tension may be useful, for instance, when approximating the walls of the access body lumen and thegallbladder 14, during the insertion of a delivery catheter (not shown), and delivery and/or deployment of a conduit. Thefeature 2118 on the distal end of aguidewire 2182 that provides for retention may have a number of different shapes, such as a “T” (FIG. 21A ), an arrow head (FIG. 21B ), a flat spiral (FIG. 21C ), a funnel-shaped spiral (FIG. 21D ), a folding compliant tag (FIG. 21E ), a grappling hook (FIG. 21F ), spreading wings (FIG. 21G ), or a whale's tail (FIG. 21H ). A retention feature may be engaged by first inserting the guidewire 2114 into the gallbladder lumen, then pulling back on the guidewire 2114 until the retention feature engages with the gallbladder wall. The guidewire is typically made of Nitinol, however it may be comprised of any material that is capable of elastically bending with the required radii and supporting the required tension in a thin, small profile. - All of the devices required to deliver and install a conduit may be packaged in a kit. Bundling all devices, tools, components, materials, and accessories needed to perform these procedures into a kit may enhance the usability and convenience of the devices, and also improve the safety of the procedure by encouraging clinicians to use the items believed to result in the best outcomes. The kit may be single-use or reusable, or it may incorporate some disposable single-use elements and some reusable elements. The kit may contain, but is not limited to, the following: implantable and/or non-implantable devices; delivery devices (e.g. needles, guidewires, guidance catheters, dilators, etc.); balloon inflation/deflation accessories; syringes; fluid flow, temperature, and pressure measurement instruments; scissors; scalpels; clips; ablation catheters; endoscopic tools (e.g. lithotripsy devices, snares, graspers, clamps, forceps, etc.). The kit may be supplied in a tray, which organizes and retains all items so that they can be quickly identified and used.
- The techniques and devices described in this application may prove beneficial in applications beyond their initial use in the treatment of biliary disease.
- For example, they may prove to be an effective mechanism of treating cholangitis (infection of the common bile duct 18). This condition is usually bacterial, and occurs when the bile duct is blocked by
gallstones 20 or a tumor. Traditional treatment involves the insertion a stent or drainage catheter into thecommon bile duct 18 to allow bile to drain into the duodenum from locations above the obstruction. Placement of a conduit into thegallbladder 14 may allow for an alternate method of draining bile and/or other fluids into the duodenum. Any blockage in thecommon bile duct 18 between the entrance of the cystic duct and the duodenum may be treated in this way. SeeFIG. 2 . - Another use of the devices and techniques described elsewhere in this application may be to create anastomoses between any body lumens in proximity to one another. This may include, but is not limited to: small bowel to small bowel anastomoses, small bowel to large bowel anastomoses, large bowel to large bowel anastomoses, and stomach to small bowel anastomoses. Additionally, creating a conduit between the stomach and other body lumens may be useful and effective for treating and/or managing obesity.
- Another use of the devices and techniques described herein is for drainage of any body lumen into another body lumen in proximity, for example, the drainage of pancreatic pseudocysts.
- While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (156)
1. A device for treating biliary disease comprising: a component configured for deployment between a gallbladder and a location within a gastrointestinal tract of a patient, the component having a proximal end and a distal end with a lumen extending therethrough.
2. The device of claim 1 wherein a conduit is formed between a gallbladder lumen and a target location within the gastrointestinal tract.
3. The device of claim 2 wherein the target location within the gastrointestinal tract is proximal to a duodenum.
4. The device of claim 1 wherein the device is formed from a bioresorbable material.
5. The device of claim 1 wherein the device is removable.
6. The device of claim 1 wherein the device is expandable.
7. The device of claim 1 further comprising one or more configurations selected from a deployment configuration, a delivery configuration and a final configuration.
8. The device of claim 7 further comprising a variable profile.
9. The device of claim 1 wherein a cross-sectional area of the device is variable along a length.
10. The device of claim 1 wherein the device is configured for deployment by at least one of an endoscope, a needle, a guidewire, a guidance catheter and a dilatation catheter.
11. The device of claim 1 further comprising a flareable end.
12. (canceled)
13. The device of claim 1 further comprising a configurable retainable feature.
14. The device of claim 1 wherein the component has one or more clips configured to secure the component at one or more positions.
15. (canceled)
16. The device of claim 1 wherein the lumen is configurable to provide restrictable fluid flow.
17. The device of claim 16 further comprising one or more fluid control components.
18. The device of claim 1 further comprising an enlargeable portion comprising two or more legs.
19. The device of claim 1 further comprising a valve.
20. The device of claim 19 wherein the valve is at least one of a flow-restrictor and a one-way valve.
21. The device of claim 1 wherein the device is flexible.
22. The device of claim 1 wherein the device is an elongate tube adapted and configured to extend into the gastrointestinal tract.
23. The device of claim 22 wherein the tube is patent at a first end.
24. The device of claim 23 wherein the patent first end is adjacent the gallbladder.
25. The device of claim 22 wherein the tube is not patent at a second end.
26. The device of claim 22 wherein the tube has an adjustable length.
27. A biliary disease treatment device comprising:
an implant adapted to be delivered by an endoscope to a gastrointestinal site in proximity to a gallbladder, and further adapted to form a conduit between the gastrointestinal site and the gallbladder.
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)
50. (canceled)
51. (canceled)
52. A method for treating biliary disease comprising:
a. creating a duct or fistula between a gallbladder lumen and a portion of a gastrointestinal tract; and
b. providing for drainage from the gallbladder to the gastrointestinal tract.
53. The method of claim 52 further comprising the step of delivering a substance to the gallbladder via the duct.
54. (canceled)
55. The method of claim 53 wherein the substances are one or more of antibiotics, inflammatory and anti-inflammatory agents.
56. (canceled)
57. The method of claim 52 further comprising the step of localizing the gallbladder via endoscopic ultrasound.
58. The method of claim 52 further comprising the step of accessing the gallbladder via the gastrointestinal tract.
59. The method of claim 58 wherein the step of accessing is performed in the gastrointestinal tract at a duodenum.
60. The method of claim 52 further comprising the step of removing gallstones.
61. The method of claim 52 further comprising the step of altering gallstones.
62. The method of claim 61 further comprising the step of removing the altered gallstones.
63. (canceled)
64. The method of claim 52 further comprising the step of delivering a device to the gallbladder through the created duct.
65. The method of claim 64 wherein the delivered device is one or more of a stent, a drug-coated stent, and a catheter.
66. The method of claim 52 wherein the biliary disease is treated without removal of the gallbladder.
67. The method of claim 52 further comprising the step of visualizing a treatment area.
68. The method of claim 52 wherein the step of creating the duct further comprises the step of inserting a device in communication between the gastrointestinal tract and the gallbladder lumen.
69. The method of claim 52 wherein the step of creating the duct between a gallbladder lumen and a portion of a gastrointestinal tract comprises the step of inserting a conduit between the gallbladder lumen and the portion of the intestinal tract.
70. The method of claim 69 further comprising the step of forming a biological duct in situ from a patient's tissue.
71. The method of claim 70 wherein the step of inserting a conduit between the gallbladder lumen and the portion of the gallbladder tract occurs at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time.
72. The method of claim 52 further comprising the step of anchoring the device in place.
73. The method of claim 52 further comprising the step of changing the device from a delivery configuration to a deployment configuration.
74. The method of claim 52 further comprising the step of changing the device from a delivery configuration to a final configuration.
75. The method of claim 52 further comprising the step of changing the device from a deployment configuration to a final configuration.
76. The method of claim 52 further comprising the step of reducing a cross-sectional profile of the device.
77. The method of claim 52 further comprising the step of delivering the device via at least one of an endoscope, a needle, a guidewire, a guidance catheter and a dilatation catheter.
78. The method of claim 52 further comprising the step of providing a seal to prevent fluid from leaking into a peritoneum.
79. The method of claim 52 further comprising the step of restricting fluid flow from the gallbladder lumen to the gastrointestinal tract.
80. The method of claim 79 further comprising the step of operating a valve to restrict fluid flow.
81. (canceled)
82. (canceled)
83. (canceled)
84. (canceled)
85. (canceled)
86. (canceled)
87. (canceled)
88. (canceled)
89. (canceled)
90. A method of delivering a device to treat biliary disease comprising:
a. using an endoscope to place at least one of a guidewire, a needle, a guidance catheter, and a dilatation catheter between an access lumen in a body and a gallbladder;
b. inserting a delivery catheter over the at least one of guidewire, needle, guidance catheter, and dilatation catheter and into the gallbladder;
c. delivering a conduit on the catheter; and
d. positioning the conduit between the access lumen in the body and the gallbladder to create a lumen therebetween.
91. The method of claim 90 further comprising the step of passively retaining a distal end of the guidewire in the gallbladder while the guidewire is used to deliver additional elements.
92. The method of claim 90 further comprising the step of retaining a distal end of the guidewire within the gallbladder.
93. The method of claim 90 further comprising the step of removing gallstones through the created lumen.
94. (canceled)
95. (canceled)
96. (canceled)
97. (canceled)
98. The method of claim 90 further comprising the step of localizing the gallbladder via endoscopic ultrasound.
99. The method of claim 90 further comprising the step of accessing the gallbladder via the gastrointestinal tract.
100. The method of claim 99 wherein the step of accessing is performed in the gastrointestinal tract at a duodenum.
101. The method of claim 90 further comprising the step of removing gallstones.
102. The method of claim 90 further comprising the step of altering gallstones.
103. The method of claim 102 further comprising the step of removing the altered gallstones.
104. (canceled)
105. The method of claim 90 wherein the delivered conduit is one or more of a stent, and a drug-coated stent.
106. The method of claim 90 wherein the biliary disease is treated without removal of the gallbladder.
107. The method of claim 90 further comprising the step of visualizing a treatment area.
108. The method of claim 90 further comprising the step of forming a biological duct in situ from a patient's tissue.
109. The method of claim 108 wherein the step of positioning the conduit occurs at a first time and the step of forming the biological duct in situ from the patient's tissue occurs at a second time remote from the first time.
110. The method of claim 90 further comprising the step of anchoring the conduit in place.
111. The method of claim 90 further comprising the step of changing the conduit from a delivery configuration to a deployment configuration.
112. The method of claim 90 further comprising the step of changing the conduit from a delivery configuration to a final configuration.
113. The method of claim 90 further comprising the step of changing the conduit from a deployment configuration to a final configuration.
114. The method of claim 90 further comprising the step of reducing a cross-sectional profile of the conduit.
115. (canceled)
116. The method of claim 90 further comprising the step of restricting fluid flow from the gallbladder lumen to the gastrointestinal tract.
117. The method of claim 116 further comprising the step of operating a valve to restrict fluid flow.
118. A system for treating biliary disease comprising a device for configuring a duct between a gallbladder and a gastrointestinal tract of a patient having a proximal end and a distal end with a lumen extending therethrough between.
119. The system of claim 118 further comprising a delivery mechanism for delivering a substance.
120. The system of claim 118 wherein a conduit is formed between a gallbladder lumen and a target location within the gastrointestinal tract.
121. The system of claim 120 wherein the target location within the gastrointestinal tract is proximal to a duodenum.
122. (canceled)
123. The system of claim 118 wherein the device is removable.
124. The system of claim 118 wherein the device is expandable.
125. The system of claim 118 further comprising one or more configurations selected from a deployment configuration, a delivery configuration and a final configuration.
126. The system of claim 125 further comprising a variable profile.
127. The system of claim 118 wherein a cross-sectional area of the device is variable along a length.
128. The system of claim 118 wherein the device is configured for deployment by at least one of an endoscope, needle, guidewire, guidance catheter and a dilatation catheter.
129. The system of claim 118 further comprising a flareable end.
130. (canceled)
131. The system of claim 118 further comprising a configurable retainable feature.
132. The system of claim 118 wherein the component has one or more clips configured to secure the component at one or more positions.
133. (canceled)
134. The system of claim 118 wherein the lumen is configurable to provide restrictable fluid flow.
135. The system of claim 134 further comprising one or more fluid control components.
136. The system of claim 118 further comprising an enlargeable portion comprising two or more legs.
137. The system of claim 118 further comprising a valve.
138. The system of claim 137 wherein the valve is at least one of a flow-restrictor or one-way valve.
139. The system of claim 118 wherein the device is flexible.
140. The system of claim 118 wherein the device is an elongate tube adapted and configured to extend into the gastrointestinal tract.
141. The system of claim 140 wherein the tube is patent at a first end.
142. The system of claim 141 wherein the patent first end is adjacent the gallbladder.
143. The system of claim 140 wherein the tube is not patent at a second end.
144. The system of claim 140 wherein the tube has an adjustable length.
145. The system of claim 118 further comprising an endoscope.
146. The system of claim 145 wherein the endoscope further comprises an ultrasound device.
147. A kit for treating biliary disease comprising:
(a) a duct forming component positioned between a gallbladder and a gastrointestinal tract; and optionally
(b) a compound for delivery to a tissue.
148. (canceled)
149. (canceled)
150. (canceled)
151. (canceled)
152. (canceled)
153. (canceled)
154. (canceled)
155. (canceled)
156. (canceled)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/277,491 US20090143713A1 (en) | 2007-11-30 | 2008-11-25 | Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor |
PCT/US2008/084888 WO2009073521A2 (en) | 2007-11-30 | 2008-11-26 | Biliary shunts, delivery systems, methods of using the same, and kits therefor |
EP08856414A EP2222364A4 (en) | 2007-11-30 | 2008-11-26 | Biliary shunts, delivery systems, methods of using the same, and kits therefor |
GB0821930A GB2460287A (en) | 2007-11-30 | 2008-12-01 | Biliary shunt to connect gall bladder and gastrointestinal tract |
US12/951,803 US9282968B2 (en) | 2007-11-30 | 2010-11-22 | Applicator for endoscopic treatment of biliary disease |
US13/439,251 US9486219B2 (en) | 2007-11-30 | 2012-04-04 | Biliary shunts, delivery systems, methods of using the same and kits therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99168207P | 2007-11-30 | 2007-11-30 | |
US3336808P | 2008-03-03 | 2008-03-03 | |
US12/277,491 US20090143713A1 (en) | 2007-11-30 | 2008-11-25 | Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/439,251 Continuation US9486219B2 (en) | 2007-11-30 | 2012-04-04 | Biliary shunts, delivery systems, methods of using the same and kits therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090143713A1 true US20090143713A1 (en) | 2009-06-04 |
Family
ID=40676480
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/277,491 Abandoned US20090143713A1 (en) | 2007-11-30 | 2008-11-25 | Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor |
US12/277,443 Abandoned US20090143760A1 (en) | 2007-11-30 | 2008-11-25 | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US12/277,338 Abandoned US20090143759A1 (en) | 2007-11-30 | 2008-11-25 | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US12/951,803 Expired - Fee Related US9282968B2 (en) | 2007-11-30 | 2010-11-22 | Applicator for endoscopic treatment of biliary disease |
US12/959,264 Abandoned US20110071566A1 (en) | 2007-11-30 | 2010-12-02 | Methods, devices, kits and systems for defunctionalizing the cystic duct |
US13/410,281 Abandoned US20120289880A1 (en) | 2007-11-30 | 2012-03-01 | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US13/439,251 Expired - Fee Related US9486219B2 (en) | 2007-11-30 | 2012-04-04 | Biliary shunts, delivery systems, methods of using the same and kits therefor |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/277,443 Abandoned US20090143760A1 (en) | 2007-11-30 | 2008-11-25 | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US12/277,338 Abandoned US20090143759A1 (en) | 2007-11-30 | 2008-11-25 | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US12/951,803 Expired - Fee Related US9282968B2 (en) | 2007-11-30 | 2010-11-22 | Applicator for endoscopic treatment of biliary disease |
US12/959,264 Abandoned US20110071566A1 (en) | 2007-11-30 | 2010-12-02 | Methods, devices, kits and systems for defunctionalizing the cystic duct |
US13/410,281 Abandoned US20120289880A1 (en) | 2007-11-30 | 2012-03-01 | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US13/439,251 Expired - Fee Related US9486219B2 (en) | 2007-11-30 | 2012-04-04 | Biliary shunts, delivery systems, methods of using the same and kits therefor |
Country Status (4)
Country | Link |
---|---|
US (7) | US20090143713A1 (en) |
EP (1) | EP2222364A4 (en) |
GB (1) | GB2460287A (en) |
WO (3) | WO2009073515A2 (en) |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050228413A1 (en) * | 2004-04-12 | 2005-10-13 | Binmoeller Kenneth F | Automated transluminal tissue targeting and anchoring devices and methods |
US20090143760A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US20110040324A1 (en) * | 2008-03-17 | 2011-02-17 | Mccarthy Patrick M | Devices and methods for percutaneous access, hemostasis, and closure |
US20110054381A1 (en) * | 2009-05-29 | 2011-03-03 | Jacques Van Dam | Biliary shunts, delivery systems, and methods of using the same |
US20110071459A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power Saving Glaucoma Drainage Device |
US20110071456A1 (en) * | 2009-09-21 | 2011-03-24 | Rickard Matthew J A | Lumen Clearing Valve For Glaucoma Drainage Device |
US20110137394A1 (en) * | 2009-05-29 | 2011-06-09 | Xlumena, Inc. | Methods and systems for penetrating adjacent tissue layers |
WO2012071031A1 (en) * | 2010-11-23 | 2012-05-31 | Treus Medical, Inc | Biliary shunts, delivery systems, and methods of using the same |
US20120136426A1 (en) * | 2009-05-29 | 2012-05-31 | Hoang Phan | Apparatus and method for deploying stent across adjacent tissue layers |
US20130066253A1 (en) * | 2011-01-27 | 2013-03-14 | Medtronic Xomed, Inc. | Adjustment for hydrocephalus shunt valve |
US8425539B2 (en) | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
US20130116614A1 (en) * | 2010-01-22 | 2013-05-09 | Medtronic Vascular, Inc. | Methods and Apparatus for Providing an Arteriovenous Fistula |
US8454632B2 (en) | 2008-05-12 | 2013-06-04 | Xlumena, Inc. | Tissue anchor for securing tissue layers |
US20130296765A1 (en) * | 2010-10-18 | 2013-11-07 | Allergan, Inc. | Intragastric implants with duodenal anchors |
US8579848B2 (en) | 2011-12-09 | 2013-11-12 | Alcon Research, Ltd. | Active drainage systems with pressure-driven valves and electronically-driven pump |
US8585631B2 (en) | 2011-10-18 | 2013-11-19 | Alcon Research, Ltd. | Active bimodal valve system for real-time IOP control |
US8603024B2 (en) | 2011-12-12 | 2013-12-10 | Alcon Research, Ltd. | Glaucoma drainage devices including vario-stable valves and associated systems and methods |
US8652085B2 (en) | 2012-07-02 | 2014-02-18 | Alcon Research, Ltd. | Reduction of gas escape in membrane actuators |
US8808224B2 (en) | 2009-09-21 | 2014-08-19 | Alcon Research, Ltd. | Glaucoma drainage device with pump |
US8840578B2 (en) | 2011-12-09 | 2014-09-23 | Alcon Research, Ltd. | Multilayer membrane actuators |
US8986240B2 (en) | 2012-02-14 | 2015-03-24 | Alcon Research, Ltd. | Corrugated membrane actuators |
US8998838B2 (en) | 2012-03-29 | 2015-04-07 | Alcon Research, Ltd. | Adjustable valve for IOP control with reed valve |
JP2015066221A (en) * | 2013-09-30 | 2015-04-13 | 日本ゼオン株式会社 | Stent for bypass between hollow organs |
DE102013112437A1 (en) * | 2013-11-13 | 2015-05-13 | Universität Rostock | Biliary and pancreatic duct drainage |
US20150257932A1 (en) * | 2013-11-25 | 2015-09-17 | Innfocus, Inc. | Methods, Systems and Devices for Treating Glaucoma |
US9155653B2 (en) | 2012-02-14 | 2015-10-13 | Alcon Research, Ltd. | Pressure-driven membrane valve for pressure control system |
US20150313596A1 (en) * | 2014-05-02 | 2015-11-05 | W. L. Gore & Associates, Inc. | Anastomosis Devices |
US9198791B2 (en) | 2010-07-22 | 2015-12-01 | Endobetix Ltd. | Pancreaticobiliary diversion device |
US9226851B2 (en) | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US9283115B2 (en) | 2013-08-26 | 2016-03-15 | Novartis Ag | Passive to active staged drainage device |
US9289324B2 (en) | 2013-08-26 | 2016-03-22 | Novartis Ag | Externally adjustable passive drainage device |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
US9364259B2 (en) | 2009-04-21 | 2016-06-14 | Xlumena, Inc. | System and method for delivering expanding trocar through a sheath |
US9381041B2 (en) | 2009-04-21 | 2016-07-05 | Xlumena, Inc. | Methods and devices for access across adjacent tissue layers |
US9528633B2 (en) | 2012-12-17 | 2016-12-27 | Novartis Ag | MEMS check valve |
US20170007276A1 (en) * | 2015-07-07 | 2017-01-12 | Empire Technology Development Llc | Gallstone removal through cholecystoduodenal fistula by anastomosis device |
US9572712B2 (en) | 2012-12-17 | 2017-02-21 | Novartis Ag | Osmotically actuated fluidic valve |
US9603742B2 (en) | 2014-03-13 | 2017-03-28 | Novartis Ag | Remote magnetic driven flow system |
US9615970B2 (en) | 2009-09-21 | 2017-04-11 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US9622910B2 (en) | 2011-12-12 | 2017-04-18 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven values |
US20170119365A1 (en) * | 2015-11-03 | 2017-05-04 | W. L. Gore & Associates, Inc. | Endoscopic organ manipulation devices and methods |
US9655777B2 (en) | 2015-04-07 | 2017-05-23 | Novartis Ag | System and method for diagphragm pumping using heating element |
US9681983B2 (en) | 2014-03-13 | 2017-06-20 | Novartis Ag | Debris clearance system for an ocular implant |
US20180078745A1 (en) * | 2016-09-19 | 2018-03-22 | Boston Scientific Scimed, Inc. | Anastomotic drainage stent |
US10092388B2 (en) | 2011-12-15 | 2018-10-09 | Cook Medical Technologies Llc | Anti-leakage prosthesis |
US10213329B2 (en) | 2011-08-12 | 2019-02-26 | W. L. Gore & Associates, Inc. | Evertable sheath devices, systems, and methods |
JP2019205931A (en) * | 2013-02-21 | 2019-12-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Stent for forming anastomosis and medical device comprising the same |
EP3624729A4 (en) * | 2017-05-19 | 2020-03-25 | Mayo Foundation for Medical Education and Research | Methods and materials for treating urinary calculi |
CN110916851A (en) * | 2019-11-29 | 2020-03-27 | 复旦大学附属中山医院 | Universal heart valve intervention forming system |
US10610664B2 (en) | 2015-07-20 | 2020-04-07 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
JP2020092948A (en) * | 2018-12-14 | 2020-06-18 | 住友ベークライト株式会社 | Anchor stent |
US10722341B2 (en) | 2014-06-18 | 2020-07-28 | Boston Scientific Scimed, Inc. | Biliary stents and methods |
US10765834B2 (en) * | 2015-07-20 | 2020-09-08 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US10779967B2 (en) | 2017-03-30 | 2020-09-22 | Boston Scientific Scimed, Inc. | Stents with dual tissue-wall anchoring features |
US10799668B2 (en) | 2015-07-20 | 2020-10-13 | Strataca Systems Limited | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function |
KR20200126047A (en) * | 2019-04-29 | 2020-11-06 | 인제대학교 산학협력단 | Balloon fixation type peritoneum-bladder shunt catheter for intraperitoneal ascites drain to bladder |
US10918827B2 (en) | 2015-07-20 | 2021-02-16 | Strataca Systems Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
US10926062B2 (en) | 2015-07-20 | 2021-02-23 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
WO2021055266A1 (en) * | 2019-09-19 | 2021-03-25 | Edwards Lifesciences Corporation | Low-stress compressible implants |
US10980663B2 (en) | 2011-03-08 | 2021-04-20 | W. L. Gore & Associates, Inc. | Medical device for use with a stoma |
US11000283B2 (en) | 2014-05-28 | 2021-05-11 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
CN112972784A (en) * | 2021-02-05 | 2021-06-18 | 首都医科大学附属北京世纪坛医院 | Pancreatic juice complete external drainage pancreas duodenectomy and pancreatic juice drainage back transfusion device |
US11040172B2 (en) | 2015-07-20 | 2021-06-22 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11040180B2 (en) | 2015-07-20 | 2021-06-22 | Strataca Systems Limited | Systems, kits and methods for inducing negative pressure to increase renal function |
US11129617B2 (en) | 2008-05-12 | 2021-09-28 | Boston Scientific Scimed, Inc. | Tissue anchor for securing tissue layers |
US11134830B2 (en) * | 2016-12-27 | 2021-10-05 | Boston Scientific Scimed, Inc. | Medical device delivery system and methods of use |
US11166806B2 (en) | 2014-01-10 | 2021-11-09 | W. L. Gore & Associates, Inc. | Implantable intraluminal device |
US11229771B2 (en) | 2015-07-20 | 2022-01-25 | Roivios Limited | Percutaneous ureteral catheter |
US11439396B2 (en) | 2014-05-02 | 2022-09-13 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
US11471583B2 (en) | 2015-07-20 | 2022-10-18 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
US11541205B2 (en) | 2015-07-20 | 2023-01-03 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
US11540933B2 (en) | 2017-10-11 | 2023-01-03 | W. L. Gore & Associates, Inc. | Implantable medical device constraint and deployment apparatus |
US11712230B2 (en) | 2014-05-02 | 2023-08-01 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
US11724075B2 (en) | 2017-04-18 | 2023-08-15 | W. L. Gore & Associates, Inc. | Deployment constraining sheath that enables staged deployment by device section |
US11801155B2 (en) | 2014-03-06 | 2023-10-31 | W. L. Gore & Associates, Inc. | Implantable medical device constraint and deployment apparatus |
US11903856B1 (en) | 2013-03-05 | 2024-02-20 | W. L. Gore & Associates, Inc. | Tapered sleeve |
US11918754B2 (en) | 2021-02-11 | 2024-03-05 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US20100222750A1 (en) * | 2009-02-27 | 2010-09-02 | Vanderbilt University | Replenishable drug delivery implant for bone and cartilage |
US8277417B2 (en) * | 2009-09-23 | 2012-10-02 | James J. Fedinec | Central venous catheter kit with line gripping and needle localizing devices |
US20110106225A1 (en) * | 2009-10-29 | 2011-05-05 | Elmer Lucas B | Method For Surgically Treating A Patient By Deactivating A Portion Of The Digestive Enzymes |
US10512761B2 (en) * | 2009-12-02 | 2019-12-24 | Renovorx, Inc. | Methods for delivery of therapeutic materials to treat pancreatic cancer |
JP2013537434A (en) * | 2010-05-08 | 2013-10-03 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Devices and methods for treating gallstones |
WO2011141800A1 (en) | 2010-05-10 | 2011-11-17 | Endosense S.A. | Irrigated finned ablation head |
CN103118607B (en) * | 2010-07-16 | 2015-09-23 | 伊西康内外科公司 | Bile is guided to the device of enteral from gallbladder |
CN103002815A (en) * | 2010-07-16 | 2013-03-27 | 伊西康内外科公司 | A device for translumenal diversion of bile |
US8535259B2 (en) * | 2010-12-29 | 2013-09-17 | Ethicon Endo-Surgery, Inc. | Methods for biliary diversion |
WO2013004264A1 (en) * | 2011-07-01 | 2013-01-10 | Ethicon Endo-Surgery, Inc. | A method and device for creating an alternative bile flow path |
CN104780932A (en) | 2012-02-29 | 2015-07-15 | 伊西康内外科公司 | Compositions of microbiota and methods related thereto |
EP3943044B1 (en) | 2013-02-28 | 2022-12-21 | Boston Scientific Scimed, Inc. | Medical devices for use along the biliary and/or pancreatic tract |
US9415196B2 (en) * | 2013-03-13 | 2016-08-16 | Boston Scientific Scimed, Inc. | Pancreatic stent drainage system |
CN104586472B (en) * | 2015-02-13 | 2016-08-31 | 中南大学湘雅医院 | A kind of calculus stopper in the bile duct that choledochoscope is placed |
CA2977681A1 (en) | 2015-03-05 | 2016-09-09 | Merit Medical Systems, Inc. | Vascular prosthesis deployment device and method of use |
US10470906B2 (en) | 2015-09-15 | 2019-11-12 | Merit Medical Systems, Inc. | Implantable device delivery system |
US10130368B2 (en) * | 2016-04-01 | 2018-11-20 | Ethicon, Inc. | Expandable compression rings for improved anastomotic joining of tissues |
WO2018064325A1 (en) | 2016-09-29 | 2018-04-05 | Merit Medical Systems, Inc. | Pliant members for receiving and aiding in the deployment of vascular prostheses |
US11135050B2 (en) | 2016-10-04 | 2021-10-05 | Boston Scientific Scimed, Inc. | Stent including anchoring members |
EP3595596B1 (en) | 2017-03-15 | 2023-09-06 | Merit Medical Systems, Inc. | Transluminal delivery devices and related kits |
WO2018170064A1 (en) | 2017-03-15 | 2018-09-20 | Merit Medical Systems, Inc. | Transluminal stents and related methods |
USD836194S1 (en) | 2017-03-21 | 2018-12-18 | Merit Medical Systems, Inc. | Stent deployment device |
KR20230062885A (en) * | 2017-06-20 | 2023-05-09 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Systems for creating permanent drainage fistula |
US20190053886A1 (en) * | 2017-08-15 | 2019-02-21 | Covidien Lp | Methods and tools for treating diseased tissue |
WO2019055800A1 (en) * | 2017-09-14 | 2019-03-21 | Regents Of The University Of California | Cryoablation devices and related methods |
JP7066846B2 (en) * | 2018-01-11 | 2022-05-13 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Systems, methods and equipment for connecting non-adhesive structures |
CN108030996B (en) * | 2018-01-19 | 2020-06-30 | 北京大学第三医院 | Integrated biliary tract self-taking-off internal drainage device |
AU2019218889B2 (en) * | 2018-02-08 | 2023-12-21 | Texas Medical Center | Gallbladder defunctionalization devices and methods |
RU2693679C1 (en) * | 2018-03-19 | 2019-07-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) | Device for occlusion of gallbladder perforation during laparoscopic cholecystectomy |
CN108815683A (en) * | 2018-04-11 | 2018-11-16 | 深圳希思凯科技有限公司 | A kind of device that treating gall stone and its application method and application |
EA038562B1 (en) * | 2018-04-17 | 2021-09-15 | Саидилхом Мухтор Ахмадзода | Method of cholecystectomy - cryo-cholecystectomy |
KR20230141909A (en) | 2019-01-07 | 2023-10-10 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Stent with anti-migration feature |
US20230363811A1 (en) * | 2020-09-25 | 2023-11-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Gallbladder cryoablation device and method |
US20240016637A1 (en) * | 2022-07-14 | 2024-01-18 | Boston Scientific Scimed, Inc. | Anti-migration stent |
Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2127903A (en) * | 1936-05-05 | 1938-08-23 | Davis & Geck Inc | Tube for surgical purposes and method of preparing and using the same |
US3741333A (en) * | 1969-01-23 | 1973-06-26 | Geophysique Cie Gle | Generators of fluid wave trains |
US3818511A (en) * | 1972-11-17 | 1974-06-25 | Medical Prod Corp | Medical prosthesis for ducts or conduits |
US3834394A (en) * | 1969-11-21 | 1974-09-10 | R Sessions | Occlusion device and method and apparatus for inserting the same |
US3933040A (en) * | 1973-11-07 | 1976-01-20 | Metco, Inc. | Flowmeter |
US4085757A (en) * | 1976-04-29 | 1978-04-25 | P Pevsner | Miniature balloon catheter method and apparatus |
US4263917A (en) * | 1979-04-06 | 1981-04-28 | Moss James P | Method of sealing bile duct during cholangiography |
US4348066A (en) * | 1979-06-11 | 1982-09-07 | The Garrett Corporation | Foil bearing mounting |
US4352358A (en) * | 1979-12-28 | 1982-10-05 | Angelchik Jean P | Apparatus for effecting anastomotic procedures |
US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4966294A (en) * | 1990-01-16 | 1990-10-30 | Fabri-Kal Corporation | Tamper-evident closure for wide mouth container |
US4994066A (en) * | 1988-10-07 | 1991-02-19 | Voss Gene A | Prostatic stent |
US5197948A (en) * | 1991-01-03 | 1993-03-30 | Kamran Ghodsian | Intra-abdominal organ manipulator, irrigator and aspirator |
US5201746A (en) * | 1991-10-16 | 1993-04-13 | United States Surgical Corporation | Surgical hemostatic clip |
US5334210A (en) * | 1993-04-09 | 1994-08-02 | Cook Incorporated | Vascular occlusion assembly |
US5443449A (en) * | 1991-03-01 | 1995-08-22 | Applied Medical Resources Corporation | Cholangiography catheter |
US5454788A (en) * | 1991-04-24 | 1995-10-03 | Baxter International Inc. | Exchangeable integrated-wire balloon catheter |
US5514088A (en) * | 1986-06-09 | 1996-05-07 | Development Collaborative Corporation | Apparatus, and method for chemical contact dissolution of gallstones |
US5632762A (en) * | 1995-11-09 | 1997-05-27 | Hemodynamics, Inc. | Ostial stent balloon |
US5643254A (en) * | 1994-03-03 | 1997-07-01 | Target Therapeutics, Inc. | Endovascular embolic device detachment detection method |
US5709224A (en) * | 1995-06-07 | 1998-01-20 | Radiotherapeutics Corporation | Method and device for permanent vessel occlusion |
US5743905A (en) * | 1995-07-07 | 1998-04-28 | Target Therapeutics, Inc. | Partially insulated occlusion device |
US5755769A (en) * | 1992-03-12 | 1998-05-26 | Laboratoire Perouse Implant | Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof |
US5776126A (en) * | 1993-09-23 | 1998-07-07 | Wilk; Peter J. | Laparoscopic surgical apparatus and associated method |
US5817046A (en) * | 1997-07-14 | 1998-10-06 | Delcath Systems, Inc. | Apparatus and method for isolated pelvic perfusion |
US5860426A (en) * | 1996-11-06 | 1999-01-19 | Kleiman; Aldo Sergio | Cholecystoscopic cannula and cholecystoscopic gallbladder laser-sclerosis procedure |
US5876432A (en) * | 1994-04-01 | 1999-03-02 | Gore Enterprise Holdings, Inc. | Self-expandable helical intravascular stent and stent-graft |
US6019757A (en) * | 1995-07-07 | 2000-02-01 | Target Therapeutics, Inc. | Endoluminal electro-occlusion detection apparatus and method |
US6241762B1 (en) * | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6246914B1 (en) * | 1999-08-12 | 2001-06-12 | Irvine Biomedical, Inc. | High torque catheter and methods thereof |
US6245101B1 (en) * | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
US6283992B1 (en) * | 1995-11-27 | 2001-09-04 | Schneider (Europe) Gmbh | Conical stent |
US6406491B1 (en) * | 1999-05-04 | 2002-06-18 | Heartstent Corporation | Compliant transmyocardial implant |
US6409755B1 (en) * | 1997-05-29 | 2002-06-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6416545B1 (en) * | 1996-04-09 | 2002-07-09 | Endocare, Inc. | Urological stent therapy system and method |
US20020095110A1 (en) * | 2000-10-11 | 2002-07-18 | Vanney Guy P. | Stabilized transmyocardial implant |
US6468303B1 (en) * | 2000-03-27 | 2002-10-22 | Aga Medical Corporation | Retrievable self expanding shunt |
US20020156523A1 (en) * | 1994-08-31 | 2002-10-24 | Lilip Lau | Exterior supported self-expanding stent-graft |
US20030045828A1 (en) * | 1998-01-30 | 2003-03-06 | Wilk Peter J. | Left ventricular conduits to coronary arteries and methods for coronary bypass |
US20030055484A1 (en) * | 1994-08-31 | 2003-03-20 | Lilip Lau | Exterior supported self-expanding stent-graft |
US6544291B2 (en) * | 1997-12-09 | 2003-04-08 | Thomas V. Taylor | Sutureless gastroesophageal anti-reflux valve prosthesis and tool for peroral implantation thereof |
US20030069533A1 (en) * | 2001-10-10 | 2003-04-10 | Hiroshi Kakutani | Endoscopic transduodenal biliary drainage system |
US20030069606A1 (en) * | 2001-06-15 | 2003-04-10 | Girouard Steven D. | Pulmonary vein stent for treating atrial fibrillation |
US20030083734A1 (en) * | 2001-10-25 | 2003-05-01 | Curative Ag | Stent |
US6585754B2 (en) * | 2001-05-29 | 2003-07-01 | Scimed Life Systems, Inc. | Absorbable implantable vaso-occlusive member |
US6599299B2 (en) * | 2001-06-26 | 2003-07-29 | Leonard S. Schultz | Device and method for body lumen occlusion |
US20030149472A1 (en) * | 1995-11-07 | 2003-08-07 | Leonard Pinchuk | Modular endluminal stent-grafts and methods for their use |
US6610100B2 (en) * | 1998-09-10 | 2003-08-26 | Percardia, Inc. | Designs for left ventricular conduit |
US20030163079A1 (en) * | 2002-02-25 | 2003-08-28 | Burnett Daniel Rogers | Vesicular shunt for the drainage of excess fluid |
US6616675B1 (en) * | 1996-02-02 | 2003-09-09 | Transvascular, Inc. | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US20040093058A1 (en) * | 2002-01-28 | 2004-05-13 | Cottone Robert J. | Flared ostial endoprosthesis and delivery system |
US20040102855A1 (en) * | 2002-11-21 | 2004-05-27 | Scimed Life Systems, Inc. | Anti-reflux stent |
US6746489B2 (en) * | 1998-08-31 | 2004-06-08 | Wilson-Cook Medical Incorporated | Prosthesis having a sleeve valve |
US6764519B2 (en) * | 2000-05-26 | 2004-07-20 | Scimed Life Systems, Inc. | Ureteral stent |
US20040181150A1 (en) * | 1999-09-01 | 2004-09-16 | Bacchus Vascular, Inc. | Methods and apparatus for accessing and treating body lumens |
US20040215331A1 (en) * | 2001-12-03 | 2004-10-28 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US20050010280A1 (en) * | 2003-07-07 | 2005-01-13 | Xiabin Jing | Biodegradable common bile duct stent and the method for preparaing thereof |
US20050010275A1 (en) * | 2002-10-11 | 2005-01-13 | Sahatjian Ronald A. | Implantable medical devices |
US20050107733A1 (en) * | 2003-04-08 | 2005-05-19 | Faul John L. | Implantable arterio-venous shunt devices and methods for their use |
US20050149166A1 (en) * | 2003-11-08 | 2005-07-07 | Schaeffer Darin G. | Branch vessel prosthesis with anchoring device and method |
US20050159726A1 (en) * | 1997-10-29 | 2005-07-21 | Kensey Nash Corporation | Transmyocardial revascularization system and method of use |
US20050192659A1 (en) * | 2004-01-23 | 2005-09-01 | Terry Dahl | Apparatus and method for performing a surgical procedure |
US20050216074A1 (en) * | 2002-10-11 | 2005-09-29 | Sahatjian Ronald A | Implantable medical devices |
US20050228413A1 (en) * | 2004-04-12 | 2005-10-13 | Binmoeller Kenneth F | Automated transluminal tissue targeting and anchoring devices and methods |
US7004949B2 (en) * | 1998-08-12 | 2006-02-28 | Cardica, Inc. | Method and system for attaching a graft to a blood vessel |
US20060047337A1 (en) * | 2004-08-27 | 2006-03-02 | Brenneman Rodney A | Device and method for establishing an artificial arterio-venous fistula |
US7011095B2 (en) * | 1998-09-10 | 2006-03-14 | Percardia, Inc. | Valve designs for left ventricular conduits |
US20060106455A1 (en) * | 2004-11-12 | 2006-05-18 | Icon Interventional Systems, Inc. | Ostial stent |
US20060129221A1 (en) * | 2004-12-10 | 2006-06-15 | Medtronic, Inc. | Tunneling guide |
US20060155369A1 (en) * | 1998-09-30 | 2006-07-13 | Bard Peripheral Vascular, Inc. | Selective adherence of stent-graft coverings |
US20060235269A1 (en) * | 2005-04-15 | 2006-10-19 | The University Of Chicago | Method, apparatus and kit for bile or pancreatic duct endoscopy |
US20070016306A1 (en) * | 1998-08-31 | 2007-01-18 | Wilson-Cook Medical Inc. | Prosthesis having a sleeve valve |
US20070021828A1 (en) * | 2005-05-23 | 2007-01-25 | Jeff Krolik | Mechanically actuated stents and apparatus and methods for delivering them |
US20070038283A1 (en) * | 2004-02-06 | 2007-02-15 | Mustapha Jihad A | Ostial stent and balloon |
US20070043381A1 (en) * | 2005-08-19 | 2007-02-22 | Icon Medical Corp. | Medical device deployment instrument |
US20070043391A1 (en) * | 2003-08-22 | 2007-02-22 | Jen.Meditech Gmbh | Occlusion device and method of for its production |
US7182744B2 (en) * | 2003-04-25 | 2007-02-27 | Medtronic Vascular | Method and apparatus for aneurismal treatment |
US20070055358A1 (en) * | 2005-08-22 | 2007-03-08 | Krolik Jeffrey A | Axially compressible flared stents and apparatus and methods for delivering them |
US20070088425A1 (en) * | 2005-10-13 | 2007-04-19 | Cook Incorporated | Endoluminal prosthesis |
US20070173921A1 (en) * | 2005-10-28 | 2007-07-26 | Wholey Mark H | Flared stents and apparatus and methods for delivering them |
US20070173867A1 (en) * | 2004-08-27 | 2007-07-26 | Brenneman Rodney A | Device and method for establishing an artificial arterio-venous fistula |
US20090143760A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US20110054381A1 (en) * | 2009-05-29 | 2011-03-03 | Jacques Van Dam | Biliary shunts, delivery systems, and methods of using the same |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US701095A (en) * | 1902-01-23 | 1902-05-27 | Elmer S Shimer | Platen-shift. |
US3385300A (en) | 1965-08-10 | 1968-05-28 | Holter Company | Cervical cannula |
SU620262A1 (en) | 1977-02-21 | 1978-08-25 | Казанский Ордена Трудового Красного Знамени Государственный Медицинский Институт Им. С.В.Курашова | Method of biliodigestive shunting |
SU688185A1 (en) | 1978-05-10 | 1979-09-30 | Институт Трансплантации Органов И Тканей | Method of draining cholecystenteroanastomosis |
SU1131498A1 (en) | 1983-09-08 | 1984-12-30 | Киевский научно-исследовательский институт клинической и экспериментальной хирургии | Method of treatment of scarry strictures of common bile duct |
US4699611A (en) | 1985-04-19 | 1987-10-13 | C. R. Bard, Inc. | Biliary stent introducer |
US4781677A (en) * | 1985-07-17 | 1988-11-01 | Wilcox Gilbert M | Method of treatment utilizing a double balloon nasobiliary occlusion catheter |
US5270805A (en) * | 1986-05-16 | 1993-12-14 | Canon Kabushiki Kaisha | Data communication apparatus for converting data in accordance with a discriminated function of a destination station |
SU1634257A1 (en) | 1988-03-09 | 1991-03-15 | Киевский научно-исследовательский институт клинической и экспериментальной хирургии | Method for drainage of the biliary ducts |
SU1586687A1 (en) | 1988-06-13 | 1990-08-23 | Донецкий медицинский институт им.М.Горького | Method of draining high biliodigestive anastomosis |
US5159925A (en) * | 1988-09-09 | 1992-11-03 | Gynelab, Inc. | Cauterizing apparatus and method for laparoscopic cholecystostomy, gallbladder ablation and treatment of benign prostate hypertrophy |
US4968294A (en) * | 1989-02-09 | 1990-11-06 | Salama Fouad A | Urinary control valve and method of using same |
JPH039746A (en) * | 1989-03-27 | 1991-01-17 | Olympus Optical Co Ltd | In vivo stay type stent |
US4955859A (en) | 1989-07-07 | 1990-09-11 | C. R. Bard, Inc. | High-friction prostatic stent |
US5071419A (en) | 1990-04-30 | 1991-12-10 | Everest Medical Corporation | Percutaneous laparoscopic cholecystectomy instrument |
US5171311A (en) | 1990-04-30 | 1992-12-15 | Everest Medical Corporation | Percutaneous laparoscopic cholecystectomy instrument |
US5170805A (en) * | 1990-12-11 | 1992-12-15 | Kensey Nash Corporation | Method of destroying tissue such as a gall bladder utilizing a sclerosing agent alone or with a symphysis agent |
US5167614A (en) | 1991-10-29 | 1992-12-01 | Medical Engineering Corporation | Prostatic stent |
AU672596B2 (en) | 1992-02-14 | 1996-10-10 | Smith & Nephew, Inc. | Polymeric screws and coatings for surgical uses |
US5536248A (en) | 1992-05-11 | 1996-07-16 | Arrow Precision Products, Inc. | Method and apparatus for electrosurgically obtaining access to the biliary tree and placing a stent therein |
US5259847A (en) | 1992-06-25 | 1993-11-09 | Montefiore Hospital And Medical Center | Catheter to maintain minimally invasive access for exchanging internal biliary stents |
US5261920A (en) | 1992-08-21 | 1993-11-16 | Ethicon, Inc. | Anvil bushing for circular stapler |
US6077271A (en) * | 1998-03-06 | 2000-06-20 | Acumed, Inc. | Bone plate vise |
US5499994A (en) | 1993-07-30 | 1996-03-19 | American Medical Systems, Inc. | Dilation device for the urethra |
US5466242A (en) * | 1994-02-02 | 1995-11-14 | Mori; Katsushi | Stent for biliary, urinary or vascular system |
US5547455A (en) * | 1994-03-30 | 1996-08-20 | Medical Media Systems | Electronically steerable endoscope |
US20030005484A1 (en) * | 1994-12-30 | 2003-01-02 | Proguard, Inc. | Microbiocidal and pesticidal aromatic aldehydes |
BE1009278A3 (en) * | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as. |
AU726713B2 (en) * | 1995-10-13 | 2000-11-16 | Transvascular, Inc. | Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
NL1001878C2 (en) | 1995-12-12 | 1997-06-17 | Cordis Europ | A method of manufacturing a stent and a tubular member and catheter therefor. |
US5769880A (en) | 1996-04-12 | 1998-06-23 | Novacept | Moisture transport system for contact electrocoagulation |
JP3968444B2 (en) | 1996-08-23 | 2007-08-29 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Stent delivery mechanism with stent fixation device |
US5921971A (en) * | 1996-09-13 | 1999-07-13 | Boston Scientific Corporation | Single operator exchange biliary catheter |
US5655548A (en) | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
AU4896797A (en) * | 1996-11-04 | 1998-05-29 | Davidson, Charles | Extendible stent apparatus and method for deploying the same |
US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
US5853419A (en) * | 1997-03-17 | 1998-12-29 | Surface Genesis, Inc. | Stent |
US6030358A (en) | 1997-08-08 | 2000-02-29 | Odland; Rick Matthew | Microcatheter and method for site specific therapy |
JP3349072B2 (en) | 1997-09-12 | 2002-11-20 | オリンパス光学工業株式会社 | Drainage tube |
WO2000012832A2 (en) | 1998-08-26 | 2000-03-09 | Molecular Geodesics, Inc. | Radially expandable device |
US7118600B2 (en) * | 1998-08-31 | 2006-10-10 | Wilson-Cook Medical, Inc. | Prosthesis having a sleeve valve |
US6458092B1 (en) | 1998-09-30 | 2002-10-01 | C. R. Bard, Inc. | Vascular inducing implants |
IT1312073B1 (en) | 1999-04-14 | 2002-04-04 | Pietro Quaretti | INTRAHEPATIC ENDOPROTESIS. |
US7422584B2 (en) | 2002-07-05 | 2008-09-09 | Broncus Technologies, Inc. | Extrapleural airway device and method |
US20020055768A1 (en) | 1999-11-24 | 2002-05-09 | Kathy Hess | Method of manufacturing a thin-layered, endovascular, polymer-covered stent device |
GB0003387D0 (en) | 2000-02-14 | 2000-04-05 | Angiomed Ag | Stent matrix |
US6953461B2 (en) * | 2002-05-16 | 2005-10-11 | Tissuelink Medical, Inc. | Fluid-assisted medical devices, systems and methods |
US6663663B2 (en) * | 2001-05-14 | 2003-12-16 | M.I. Tech Co., Ltd. | Stent |
CA2447514C (en) * | 2001-05-18 | 2010-07-06 | University College London | A flexible device for transfixing and joining tissue |
US7144363B2 (en) * | 2001-10-16 | 2006-12-05 | Extensia Medical, Inc. | Systems for heart treatment |
US20060247575A1 (en) | 2001-12-21 | 2006-11-02 | Richard Cartledge | Balloon cannulae |
US6964681B2 (en) * | 2002-01-29 | 2005-11-15 | Medtronic Vascular, Inc. | Flared stent and method of use |
US7645259B2 (en) | 2002-02-01 | 2010-01-12 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
US7647891B2 (en) | 2003-10-24 | 2010-01-19 | Pathway Technologies, Llc | Method and apparatus for creating a pathway in an animal |
RU2226364C1 (en) | 2002-10-07 | 2004-04-10 | Государственное учреждение Главный клинический госпиталь Министерства Внутренних дел Российской Федерации (некоммерческая организация) | Method for indirect access into duodenal cavity |
US20040097880A1 (en) | 2002-11-19 | 2004-05-20 | Angiodynamics, Inc. | Combination thrombolytic infusion catheter and dilator system |
US20040260386A1 (en) * | 2003-01-31 | 2004-12-23 | Shalaby Shalaby W. | Absorbable / biodegradable tubular stent and methods of making the same |
WO2004091710A1 (en) | 2003-04-14 | 2004-10-28 | Cook Incorporated | Large diameter delivery catheter/sheath |
US20050021084A1 (en) | 2003-05-19 | 2005-01-27 | Lu William Weijia | Bone treatment device and method |
US7317951B2 (en) | 2003-07-25 | 2008-01-08 | Integrated Sensing Systems, Inc. | Anchor for medical implant placement and method of manufacture |
US7704223B2 (en) | 2003-10-07 | 2010-04-27 | Northgate Technologies Inc. | System and method for delivering a substance to a body cavity |
US7255713B2 (en) | 2003-12-18 | 2007-08-14 | Malek Michel H | Systems and methods for agent delivery |
US8425539B2 (en) * | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
US7998060B2 (en) * | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US7803195B2 (en) | 2004-06-03 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
JP5178194B2 (en) * | 2004-06-14 | 2013-04-10 | ロックス メディカル, インコーポレイテッド | Devices, systems, and methods for arterio-venous fistula generation |
WO2006015091A2 (en) | 2004-07-28 | 2006-02-09 | University Of Virginia Patent Foundation | Coaxial catheter systems for transference of medium |
US7828814B2 (en) * | 2004-08-27 | 2010-11-09 | Rox Medical, Inc. | Device and method for establishing an artificial arterio-venous fistula |
US20060135963A1 (en) | 2004-09-09 | 2006-06-22 | Kick George F | Expandable gastrointestinal sheath |
US7938307B2 (en) | 2004-10-18 | 2011-05-10 | Tyco Healthcare Group Lp | Support structures and methods of using the same |
US7722629B2 (en) | 2004-10-29 | 2010-05-25 | Jeffrey W. Chambers, M.D. | System and method for catheter-based septal defect repair |
WO2006062996A2 (en) | 2004-12-08 | 2006-06-15 | Kenneth Binmoeller | Method and apparatus for performing needle guided interventions |
US20090306633A1 (en) * | 2005-01-18 | 2009-12-10 | Koninklijke Philips Electronics, N.V. | Electronically controlled capsule |
ITRM20050120A1 (en) * | 2005-03-16 | 2006-09-17 | Consiglio Nazionale Ricerche | HOLOGRAPHIC METHOD IN NUMERICAL RECONSTRUCTION TO OBTAIN A PICTURE OF A THREE-DIMENSIONAL OBJECT IN WHICH THERE ARE ALSO POINTS OUTSIDE THE DEPTH OF FIELD, AND THE HOLOGRAPHIC APPARATUS USING THIS METHOD. |
US7717936B2 (en) | 2005-04-18 | 2010-05-18 | Salviac Limited | Device for loading an embolic protection filter into a catheter |
EP1887994A2 (en) | 2005-05-23 | 2008-02-20 | Incept Llc | Mechanically actuated stents and apparatus and methods for delivering them |
ATE489060T1 (en) | 2005-06-29 | 2010-12-15 | Bipin C Patadia | SYSTEM FOR DEPLOYING A PROXIMALLY EXPANDED STENT |
EP1912592A4 (en) | 2005-07-26 | 2016-01-06 | Rox Medical Inc | Devices, systems, and methods for peripheral arteriovenous fistula creation |
EP1948280A4 (en) * | 2005-10-24 | 2011-07-06 | Andrew Young | Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases |
EP1795151A1 (en) | 2005-12-07 | 2007-06-13 | Dr. Karel Volenec - ELLA - CS | Biodegradable stent |
WO2007146021A2 (en) * | 2006-06-06 | 2007-12-21 | Cook Incorporated | Stent with a crush-resistant zone |
US9037244B2 (en) | 2007-02-13 | 2015-05-19 | Virender K. Sharma | Method and apparatus for electrical stimulation of the pancreatico-biliary system |
US20090073507A1 (en) * | 2007-09-18 | 2009-03-19 | Sharp Kabushiki Kaisha | Document reading apparatus and document reading system |
JP5082713B2 (en) * | 2007-09-19 | 2012-11-28 | コニカミノルタビジネステクノロジーズ株式会社 | Image forming apparatus and image forming method |
WO2012071031A1 (en) | 2010-11-23 | 2012-05-31 | Treus Medical, Inc | Biliary shunts, delivery systems, and methods of using the same |
-
2008
- 2008-11-25 US US12/277,491 patent/US20090143713A1/en not_active Abandoned
- 2008-11-25 US US12/277,443 patent/US20090143760A1/en not_active Abandoned
- 2008-11-25 US US12/277,338 patent/US20090143759A1/en not_active Abandoned
- 2008-11-26 WO PCT/US2008/084865 patent/WO2009073515A2/en active Application Filing
- 2008-11-26 EP EP08856414A patent/EP2222364A4/en not_active Withdrawn
- 2008-11-26 WO PCT/US2008/084888 patent/WO2009073521A2/en active Application Filing
- 2008-11-26 WO PCT/US2008/084830 patent/WO2009073507A2/en active Application Filing
- 2008-12-01 GB GB0821930A patent/GB2460287A/en not_active Withdrawn
-
2010
- 2010-11-22 US US12/951,803 patent/US9282968B2/en not_active Expired - Fee Related
- 2010-12-02 US US12/959,264 patent/US20110071566A1/en not_active Abandoned
-
2012
- 2012-03-01 US US13/410,281 patent/US20120289880A1/en not_active Abandoned
- 2012-04-04 US US13/439,251 patent/US9486219B2/en not_active Expired - Fee Related
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2127903A (en) * | 1936-05-05 | 1938-08-23 | Davis & Geck Inc | Tube for surgical purposes and method of preparing and using the same |
US3741333A (en) * | 1969-01-23 | 1973-06-26 | Geophysique Cie Gle | Generators of fluid wave trains |
US3834394A (en) * | 1969-11-21 | 1974-09-10 | R Sessions | Occlusion device and method and apparatus for inserting the same |
US3818511A (en) * | 1972-11-17 | 1974-06-25 | Medical Prod Corp | Medical prosthesis for ducts or conduits |
US3933040A (en) * | 1973-11-07 | 1976-01-20 | Metco, Inc. | Flowmeter |
US4085757A (en) * | 1976-04-29 | 1978-04-25 | P Pevsner | Miniature balloon catheter method and apparatus |
US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4263917A (en) * | 1979-04-06 | 1981-04-28 | Moss James P | Method of sealing bile duct during cholangiography |
US4348066A (en) * | 1979-06-11 | 1982-09-07 | The Garrett Corporation | Foil bearing mounting |
US4352358A (en) * | 1979-12-28 | 1982-10-05 | Angelchik Jean P | Apparatus for effecting anastomotic procedures |
US5514088A (en) * | 1986-06-09 | 1996-05-07 | Development Collaborative Corporation | Apparatus, and method for chemical contact dissolution of gallstones |
US4994066A (en) * | 1988-10-07 | 1991-02-19 | Voss Gene A | Prostatic stent |
US4966294A (en) * | 1990-01-16 | 1990-10-30 | Fabri-Kal Corporation | Tamper-evident closure for wide mouth container |
US5197948A (en) * | 1991-01-03 | 1993-03-30 | Kamran Ghodsian | Intra-abdominal organ manipulator, irrigator and aspirator |
US5443449A (en) * | 1991-03-01 | 1995-08-22 | Applied Medical Resources Corporation | Cholangiography catheter |
US5454788A (en) * | 1991-04-24 | 1995-10-03 | Baxter International Inc. | Exchangeable integrated-wire balloon catheter |
US5201746A (en) * | 1991-10-16 | 1993-04-13 | United States Surgical Corporation | Surgical hemostatic clip |
US5755769A (en) * | 1992-03-12 | 1998-05-26 | Laboratoire Perouse Implant | Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof |
US5334210A (en) * | 1993-04-09 | 1994-08-02 | Cook Incorporated | Vascular occlusion assembly |
US5776126A (en) * | 1993-09-23 | 1998-07-07 | Wilk; Peter J. | Laparoscopic surgical apparatus and associated method |
US5643254A (en) * | 1994-03-03 | 1997-07-01 | Target Therapeutics, Inc. | Endovascular embolic device detachment detection method |
US5876432A (en) * | 1994-04-01 | 1999-03-02 | Gore Enterprise Holdings, Inc. | Self-expandable helical intravascular stent and stent-graft |
US20020156523A1 (en) * | 1994-08-31 | 2002-10-24 | Lilip Lau | Exterior supported self-expanding stent-graft |
US20030055484A1 (en) * | 1994-08-31 | 2003-03-20 | Lilip Lau | Exterior supported self-expanding stent-graft |
US5709224A (en) * | 1995-06-07 | 1998-01-20 | Radiotherapeutics Corporation | Method and device for permanent vessel occlusion |
US6077261A (en) * | 1995-06-07 | 2000-06-20 | Radiotherapeutics Corporation | Device for permanent vessel occlusion |
US5743905A (en) * | 1995-07-07 | 1998-04-28 | Target Therapeutics, Inc. | Partially insulated occlusion device |
US6019757A (en) * | 1995-07-07 | 2000-02-01 | Target Therapeutics, Inc. | Endoluminal electro-occlusion detection apparatus and method |
US20030149472A1 (en) * | 1995-11-07 | 2003-08-07 | Leonard Pinchuk | Modular endluminal stent-grafts and methods for their use |
US5632762A (en) * | 1995-11-09 | 1997-05-27 | Hemodynamics, Inc. | Ostial stent balloon |
US6283992B1 (en) * | 1995-11-27 | 2001-09-04 | Schneider (Europe) Gmbh | Conical stent |
US6616675B1 (en) * | 1996-02-02 | 2003-09-09 | Transvascular, Inc. | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US6416545B1 (en) * | 1996-04-09 | 2002-07-09 | Endocare, Inc. | Urological stent therapy system and method |
US5860426A (en) * | 1996-11-06 | 1999-01-19 | Kleiman; Aldo Sergio | Cholecystoscopic cannula and cholecystoscopic gallbladder laser-sclerosis procedure |
US6409755B1 (en) * | 1997-05-29 | 2002-06-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US5817046A (en) * | 1997-07-14 | 1998-10-06 | Delcath Systems, Inc. | Apparatus and method for isolated pelvic perfusion |
US20050159726A1 (en) * | 1997-10-29 | 2005-07-21 | Kensey Nash Corporation | Transmyocardial revascularization system and method of use |
US6544291B2 (en) * | 1997-12-09 | 2003-04-08 | Thomas V. Taylor | Sutureless gastroesophageal anti-reflux valve prosthesis and tool for peroral implantation thereof |
US6558429B2 (en) * | 1997-12-09 | 2003-05-06 | Reflux Corporation | Perorally insertable gastroesophageal anti-reflux valve prosthesis and tool for implantation thereof |
US6945949B2 (en) * | 1998-01-30 | 2005-09-20 | Percardia, Inc. | Left ventricular conduits to coronary arteries and methods for coronary bypass |
US20030045828A1 (en) * | 1998-01-30 | 2003-03-06 | Wilk Peter J. | Left ventricular conduits to coronary arteries and methods for coronary bypass |
US6241762B1 (en) * | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7004949B2 (en) * | 1998-08-12 | 2006-02-28 | Cardica, Inc. | Method and system for attaching a graft to a blood vessel |
US7041110B2 (en) * | 1998-08-12 | 2006-05-09 | Cardica, Inc. | Method and system for attaching a graft to a blood vessel |
US20070016306A1 (en) * | 1998-08-31 | 2007-01-18 | Wilson-Cook Medical Inc. | Prosthesis having a sleeve valve |
US6746489B2 (en) * | 1998-08-31 | 2004-06-08 | Wilson-Cook Medical Incorporated | Prosthesis having a sleeve valve |
US20040199262A1 (en) * | 1998-08-31 | 2004-10-07 | Wilson-Cook Medical Incorporated | Prosthesis having a sleeve valve |
US6610100B2 (en) * | 1998-09-10 | 2003-08-26 | Percardia, Inc. | Designs for left ventricular conduit |
US7011095B2 (en) * | 1998-09-10 | 2006-03-14 | Percardia, Inc. | Valve designs for left ventricular conduits |
US20060155369A1 (en) * | 1998-09-30 | 2006-07-13 | Bard Peripheral Vascular, Inc. | Selective adherence of stent-graft coverings |
US6245101B1 (en) * | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
US6406491B1 (en) * | 1999-05-04 | 2002-06-18 | Heartstent Corporation | Compliant transmyocardial implant |
US6246914B1 (en) * | 1999-08-12 | 2001-06-12 | Irvine Biomedical, Inc. | High torque catheter and methods thereof |
US20040181150A1 (en) * | 1999-09-01 | 2004-09-16 | Bacchus Vascular, Inc. | Methods and apparatus for accessing and treating body lumens |
US6468303B1 (en) * | 2000-03-27 | 2002-10-22 | Aga Medical Corporation | Retrievable self expanding shunt |
US6764519B2 (en) * | 2000-05-26 | 2004-07-20 | Scimed Life Systems, Inc. | Ureteral stent |
US20020095110A1 (en) * | 2000-10-11 | 2002-07-18 | Vanney Guy P. | Stabilized transmyocardial implant |
US6585754B2 (en) * | 2001-05-29 | 2003-07-01 | Scimed Life Systems, Inc. | Absorbable implantable vaso-occlusive member |
US20030069606A1 (en) * | 2001-06-15 | 2003-04-10 | Girouard Steven D. | Pulmonary vein stent for treating atrial fibrillation |
US6599299B2 (en) * | 2001-06-26 | 2003-07-29 | Leonard S. Schultz | Device and method for body lumen occlusion |
US20040073317A1 (en) * | 2001-06-26 | 2004-04-15 | Schultz Leonard S. | Device and method for body lumen occlusion |
US20030069533A1 (en) * | 2001-10-10 | 2003-04-10 | Hiroshi Kakutani | Endoscopic transduodenal biliary drainage system |
US20030083734A1 (en) * | 2001-10-25 | 2003-05-01 | Curative Ag | Stent |
US20040215331A1 (en) * | 2001-12-03 | 2004-10-28 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US20040093058A1 (en) * | 2002-01-28 | 2004-05-13 | Cottone Robert J. | Flared ostial endoprosthesis and delivery system |
US20030163079A1 (en) * | 2002-02-25 | 2003-08-28 | Burnett Daniel Rogers | Vesicular shunt for the drainage of excess fluid |
US20050010275A1 (en) * | 2002-10-11 | 2005-01-13 | Sahatjian Ronald A. | Implantable medical devices |
US20050216074A1 (en) * | 2002-10-11 | 2005-09-29 | Sahatjian Ronald A | Implantable medical devices |
US20040102855A1 (en) * | 2002-11-21 | 2004-05-27 | Scimed Life Systems, Inc. | Anti-reflux stent |
US20050107733A1 (en) * | 2003-04-08 | 2005-05-19 | Faul John L. | Implantable arterio-venous shunt devices and methods for their use |
US7182744B2 (en) * | 2003-04-25 | 2007-02-27 | Medtronic Vascular | Method and apparatus for aneurismal treatment |
US7094260B2 (en) * | 2003-07-07 | 2006-08-22 | Changhun Institute of Applied Chemistry Chinese Academy of Science | Biodegradable common bile duct stent and the method for preparing thereof |
US20050010280A1 (en) * | 2003-07-07 | 2005-01-13 | Xiabin Jing | Biodegradable common bile duct stent and the method for preparaing thereof |
US20070043391A1 (en) * | 2003-08-22 | 2007-02-22 | Jen.Meditech Gmbh | Occlusion device and method of for its production |
US20070179592A1 (en) * | 2003-11-08 | 2007-08-02 | Schaeffer Darin G | Branch vessel prosthesis with positional indicator system and method |
US20060058864A1 (en) * | 2003-11-08 | 2006-03-16 | Schaeffer Darin G | Balloon flareable branch vessel prosthesis and method |
US20050149166A1 (en) * | 2003-11-08 | 2005-07-07 | Schaeffer Darin G. | Branch vessel prosthesis with anchoring device and method |
US20050171598A1 (en) * | 2003-11-08 | 2005-08-04 | Schaeffer Darin G. | Aorta and branch vessel stent grafts and method |
US20050192659A1 (en) * | 2004-01-23 | 2005-09-01 | Terry Dahl | Apparatus and method for performing a surgical procedure |
US20070038283A1 (en) * | 2004-02-06 | 2007-02-15 | Mustapha Jihad A | Ostial stent and balloon |
US20050228413A1 (en) * | 2004-04-12 | 2005-10-13 | Binmoeller Kenneth F | Automated transluminal tissue targeting and anchoring devices and methods |
US20070173867A1 (en) * | 2004-08-27 | 2007-07-26 | Brenneman Rodney A | Device and method for establishing an artificial arterio-venous fistula |
US20060047337A1 (en) * | 2004-08-27 | 2006-03-02 | Brenneman Rodney A | Device and method for establishing an artificial arterio-venous fistula |
US20060106455A1 (en) * | 2004-11-12 | 2006-05-18 | Icon Interventional Systems, Inc. | Ostial stent |
US20060129221A1 (en) * | 2004-12-10 | 2006-06-15 | Medtronic, Inc. | Tunneling guide |
US20060235269A1 (en) * | 2005-04-15 | 2006-10-19 | The University Of Chicago | Method, apparatus and kit for bile or pancreatic duct endoscopy |
US20070021828A1 (en) * | 2005-05-23 | 2007-01-25 | Jeff Krolik | Mechanically actuated stents and apparatus and methods for delivering them |
US20070043381A1 (en) * | 2005-08-19 | 2007-02-22 | Icon Medical Corp. | Medical device deployment instrument |
US20070055358A1 (en) * | 2005-08-22 | 2007-03-08 | Krolik Jeffrey A | Axially compressible flared stents and apparatus and methods for delivering them |
US20070067011A1 (en) * | 2005-08-22 | 2007-03-22 | Krolik Jeffrey A | Steep-taper flared stents and apparatus and methods for delivering them |
US20070073388A1 (en) * | 2005-08-22 | 2007-03-29 | Krolik Jeffrey A | Flared stents and apparatus and methods for delivering them |
US20070073376A1 (en) * | 2005-08-22 | 2007-03-29 | Krolik Jeffrey A | Steep-taper flared stents and apparatus and methods for delivering them |
US20070088425A1 (en) * | 2005-10-13 | 2007-04-19 | Cook Incorporated | Endoluminal prosthesis |
US20070173921A1 (en) * | 2005-10-28 | 2007-07-26 | Wholey Mark H | Flared stents and apparatus and methods for delivering them |
US20090143760A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US20090143759A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US20110071566A1 (en) * | 2007-11-30 | 2011-03-24 | Jacques Van Dam | Methods, devices, kits and systems for defunctionalizing the cystic duct |
US20110071350A1 (en) * | 2007-11-30 | 2011-03-24 | Jacques Van Dam | Applicator for endoscopic treatment of biliary disease |
US20110054381A1 (en) * | 2009-05-29 | 2011-03-03 | Jacques Van Dam | Biliary shunts, delivery systems, and methods of using the same |
Cited By (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11857160B2 (en) | 2004-04-12 | 2024-01-02 | Boston Scientific Scimed, Inc. | Luminal structure anchoring devices and methods |
US20050228413A1 (en) * | 2004-04-12 | 2005-10-13 | Binmoeller Kenneth F | Automated transluminal tissue targeting and anchoring devices and methods |
US8425539B2 (en) | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
US9486219B2 (en) | 2007-11-30 | 2016-11-08 | Treus Medical, Inc. | Biliary shunts, delivery systems, methods of using the same and kits therefor |
US20090143760A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder |
US20090143759A1 (en) * | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
US20110071350A1 (en) * | 2007-11-30 | 2011-03-24 | Jacques Van Dam | Applicator for endoscopic treatment of biliary disease |
US9282968B2 (en) | 2007-11-30 | 2016-03-15 | Treus Medical, Inc. | Applicator for endoscopic treatment of biliary disease |
US20110040324A1 (en) * | 2008-03-17 | 2011-02-17 | Mccarthy Patrick M | Devices and methods for percutaneous access, hemostasis, and closure |
US9554787B2 (en) | 2008-03-17 | 2017-01-31 | Northwestern University | Devices and methods for percutaneous access, hemostasis, and closure |
US8454632B2 (en) | 2008-05-12 | 2013-06-04 | Xlumena, Inc. | Tissue anchor for securing tissue layers |
US11129617B2 (en) | 2008-05-12 | 2021-09-28 | Boston Scientific Scimed, Inc. | Tissue anchor for securing tissue layers |
US11129618B2 (en) | 2008-05-12 | 2021-09-28 | Boston Scientific Scimed, Inc. | Tissue anchor for securing tissue layers |
US10076330B2 (en) | 2008-05-12 | 2018-09-18 | Xlumena, Inc. | Tissue anchor for securing tissue layers |
US9381041B2 (en) | 2009-04-21 | 2016-07-05 | Xlumena, Inc. | Methods and devices for access across adjacent tissue layers |
US9364259B2 (en) | 2009-04-21 | 2016-06-14 | Xlumena, Inc. | System and method for delivering expanding trocar through a sheath |
US10729492B2 (en) | 2009-04-21 | 2020-08-04 | Boston Scientific Scimed Inc. | Methods and devices for access across adjacent tissue layers |
US8357193B2 (en) | 2009-05-29 | 2013-01-22 | Xlumena, Inc. | Apparatus and method for deploying stent across adjacent tissue layers |
US20120136426A1 (en) * | 2009-05-29 | 2012-05-31 | Hoang Phan | Apparatus and method for deploying stent across adjacent tissue layers |
US20110137394A1 (en) * | 2009-05-29 | 2011-06-09 | Xlumena, Inc. | Methods and systems for penetrating adjacent tissue layers |
US9888926B2 (en) * | 2009-05-29 | 2018-02-13 | Boston Scientific Scimed, Inc. | Apparatus and method for deploying stent across adjacent tissue layers |
US20110054381A1 (en) * | 2009-05-29 | 2011-03-03 | Jacques Van Dam | Biliary shunts, delivery systems, and methods of using the same |
US9901347B2 (en) | 2009-05-29 | 2018-02-27 | Terus Medical, Inc. | Biliary shunts, delivery systems, and methods of using the same |
US20110071456A1 (en) * | 2009-09-21 | 2011-03-24 | Rickard Matthew J A | Lumen Clearing Valve For Glaucoma Drainage Device |
US8808224B2 (en) | 2009-09-21 | 2014-08-19 | Alcon Research, Ltd. | Glaucoma drainage device with pump |
US8721580B2 (en) * | 2009-09-21 | 2014-05-13 | Alcon Research, Ltd. | Power saving glaucoma drainage device |
US9615970B2 (en) | 2009-09-21 | 2017-04-11 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US8545431B2 (en) | 2009-09-21 | 2013-10-01 | Alcon Research, Ltd. | Lumen clearing valve for glaucoma drainage device |
US20110071459A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power Saving Glaucoma Drainage Device |
US9061115B2 (en) * | 2010-01-22 | 2015-06-23 | Medtronic Vascular, Inc. | Methods and apparatus for providing an arteriovenous fistula |
US20130116614A1 (en) * | 2010-01-22 | 2013-05-09 | Medtronic Vascular, Inc. | Methods and Apparatus for Providing an Arteriovenous Fistula |
US9198791B2 (en) | 2010-07-22 | 2015-12-01 | Endobetix Ltd. | Pancreaticobiliary diversion device |
US9668901B2 (en) * | 2010-10-18 | 2017-06-06 | Apollo Endosurgery Us, Inc. | Intragastric implants with duodenal anchors |
US20130296765A1 (en) * | 2010-10-18 | 2013-11-07 | Allergan, Inc. | Intragastric implants with duodenal anchors |
EP2643044A4 (en) * | 2010-11-23 | 2018-03-07 | Treus Medical, Inc. | Biliary shunts, delivery systems, and methods of using the same |
CN103221089A (en) * | 2010-11-23 | 2013-07-24 | 特里厄斯医疗公司 | Biliary shunts, delivery systems, and methods of using the same |
WO2012071031A1 (en) * | 2010-11-23 | 2012-05-31 | Treus Medical, Inc | Biliary shunts, delivery systems, and methods of using the same |
US10512762B2 (en) | 2011-01-27 | 2019-12-24 | Medtronic Xomed, Inc. | Adjustment for hydrocephalus shunt valve |
US20130066253A1 (en) * | 2011-01-27 | 2013-03-14 | Medtronic Xomed, Inc. | Adjustment for hydrocephalus shunt valve |
US9302082B2 (en) * | 2011-01-27 | 2016-04-05 | Medtronic Xomed, Inc. | Adjustment for hydrocephalus shunt valve |
US10980663B2 (en) | 2011-03-08 | 2021-04-20 | W. L. Gore & Associates, Inc. | Medical device for use with a stoma |
US11229539B2 (en) | 2011-08-12 | 2022-01-25 | W. L. Gore & Associates, Inc. | Evertable sheath devices, systems, and methods |
US10213329B2 (en) | 2011-08-12 | 2019-02-26 | W. L. Gore & Associates, Inc. | Evertable sheath devices, systems, and methods |
US8585631B2 (en) | 2011-10-18 | 2013-11-19 | Alcon Research, Ltd. | Active bimodal valve system for real-time IOP control |
US8840578B2 (en) | 2011-12-09 | 2014-09-23 | Alcon Research, Ltd. | Multilayer membrane actuators |
US8579848B2 (en) | 2011-12-09 | 2013-11-12 | Alcon Research, Ltd. | Active drainage systems with pressure-driven valves and electronically-driven pump |
US9622910B2 (en) | 2011-12-12 | 2017-04-18 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven values |
US8603024B2 (en) | 2011-12-12 | 2013-12-10 | Alcon Research, Ltd. | Glaucoma drainage devices including vario-stable valves and associated systems and methods |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
US10092388B2 (en) | 2011-12-15 | 2018-10-09 | Cook Medical Technologies Llc | Anti-leakage prosthesis |
US9155653B2 (en) | 2012-02-14 | 2015-10-13 | Alcon Research, Ltd. | Pressure-driven membrane valve for pressure control system |
US8986240B2 (en) | 2012-02-14 | 2015-03-24 | Alcon Research, Ltd. | Corrugated membrane actuators |
US8998838B2 (en) | 2012-03-29 | 2015-04-07 | Alcon Research, Ltd. | Adjustable valve for IOP control with reed valve |
US11432873B2 (en) | 2012-05-17 | 2022-09-06 | Boston Scientific Scimed, Inc. | Methods and devices for access across adjacent tissue layers |
US8652085B2 (en) | 2012-07-02 | 2014-02-18 | Alcon Research, Ltd. | Reduction of gas escape in membrane actuators |
US9572712B2 (en) | 2012-12-17 | 2017-02-21 | Novartis Ag | Osmotically actuated fluidic valve |
US9528633B2 (en) | 2012-12-17 | 2016-12-27 | Novartis Ag | MEMS check valve |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US10952732B2 (en) | 2013-02-21 | 2021-03-23 | Boston Scientific Scimed Inc. | Devices and methods for forming an anastomosis |
EP3669798A1 (en) * | 2013-02-21 | 2020-06-24 | Boston Scientific Scimed Inc. | Devices for forming an anastomosis |
JP2019205931A (en) * | 2013-02-21 | 2019-12-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Stent for forming anastomosis and medical device comprising the same |
US11903856B1 (en) | 2013-03-05 | 2024-02-20 | W. L. Gore & Associates, Inc. | Tapered sleeve |
US9226851B2 (en) | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US9283115B2 (en) | 2013-08-26 | 2016-03-15 | Novartis Ag | Passive to active staged drainage device |
US9289324B2 (en) | 2013-08-26 | 2016-03-22 | Novartis Ag | Externally adjustable passive drainage device |
JP2015066221A (en) * | 2013-09-30 | 2015-04-13 | 日本ゼオン株式会社 | Stent for bypass between hollow organs |
DE102013112437A1 (en) * | 2013-11-13 | 2015-05-13 | Universität Rostock | Biliary and pancreatic duct drainage |
US10010450B2 (en) * | 2013-11-25 | 2018-07-03 | Innfocus, Inc. | Methods, systems and devices for treating glaucoma |
US20150257932A1 (en) * | 2013-11-25 | 2015-09-17 | Innfocus, Inc. | Methods, Systems and Devices for Treating Glaucoma |
US11857407B2 (en) | 2014-01-10 | 2024-01-02 | W. L. Gore & Associates, Inc. | Implantable intraluminal device |
US11166806B2 (en) | 2014-01-10 | 2021-11-09 | W. L. Gore & Associates, Inc. | Implantable intraluminal device |
US11801155B2 (en) | 2014-03-06 | 2023-10-31 | W. L. Gore & Associates, Inc. | Implantable medical device constraint and deployment apparatus |
US9681983B2 (en) | 2014-03-13 | 2017-06-20 | Novartis Ag | Debris clearance system for an ocular implant |
US9603742B2 (en) | 2014-03-13 | 2017-03-28 | Novartis Ag | Remote magnetic driven flow system |
US11596409B2 (en) | 2014-05-02 | 2023-03-07 | W.L. Gore & Associates, Inc. | Anastomosis devices |
US10806458B2 (en) | 2014-05-02 | 2020-10-20 | W. L. Gore & Associates, Inc. | Anastomosis devices |
JP2019030675A (en) * | 2014-05-02 | 2019-02-28 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | Anastomosis devices |
US20150313596A1 (en) * | 2014-05-02 | 2015-11-05 | W. L. Gore & Associates, Inc. | Anastomosis Devices |
JP2017513607A (en) * | 2014-05-02 | 2017-06-01 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | Anastomosis |
US11439396B2 (en) | 2014-05-02 | 2022-09-13 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
US10004509B2 (en) * | 2014-05-02 | 2018-06-26 | W. L. Gore & Associates, Inc. | Anastomosis devices |
US11344307B2 (en) | 2014-05-02 | 2022-05-31 | W. L. Gore & Associates, Inc. | Anastomosis devices |
US11712230B2 (en) | 2014-05-02 | 2023-08-01 | W. L. Gore & Associates, Inc. | Occluder and anastomosis devices |
US9993251B2 (en) | 2014-05-02 | 2018-06-12 | W. L. Gore & Associates, Inc. | Anastomosis devices |
JP2017517309A (en) * | 2014-05-02 | 2017-06-29 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | Anastomosis instrument |
US20210228210A1 (en) * | 2014-05-28 | 2021-07-29 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
US11000283B2 (en) | 2014-05-28 | 2021-05-11 | Boston Scientific Scimed, Inc. | Catheter with radiofrequency cutting tip and heated balloon |
US11504221B2 (en) | 2014-06-18 | 2022-11-22 | Boston Scientific Scimed Inc. | Biliary stents and methods |
US10722341B2 (en) | 2014-06-18 | 2020-07-28 | Boston Scientific Scimed, Inc. | Biliary stents and methods |
US9655777B2 (en) | 2015-04-07 | 2017-05-23 | Novartis Ag | System and method for diagphragm pumping using heating element |
US20170007276A1 (en) * | 2015-07-07 | 2017-01-12 | Empire Technology Development Llc | Gallstone removal through cholecystoduodenal fistula by anastomosis device |
US10765834B2 (en) * | 2015-07-20 | 2020-09-08 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US10799668B2 (en) | 2015-07-20 | 2020-10-13 | Strataca Systems Limited | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function |
US11904121B2 (en) | 2015-07-20 | 2024-02-20 | Roivios Limited | Negative pressure therapy system |
US10918827B2 (en) | 2015-07-20 | 2021-02-16 | Strataca Systems Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
US11752300B2 (en) | 2015-07-20 | 2023-09-12 | Roivios Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
US10918825B2 (en) | 2015-07-20 | 2021-02-16 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US10926062B2 (en) | 2015-07-20 | 2021-02-23 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11904113B2 (en) | 2015-07-20 | 2024-02-20 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11040172B2 (en) | 2015-07-20 | 2021-06-22 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11040180B2 (en) | 2015-07-20 | 2021-06-22 | Strataca Systems Limited | Systems, kits and methods for inducing negative pressure to increase renal function |
US11612714B2 (en) | 2015-07-20 | 2023-03-28 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
US11896785B2 (en) | 2015-07-20 | 2024-02-13 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11077284B2 (en) | 2015-07-20 | 2021-08-03 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11541205B2 (en) | 2015-07-20 | 2023-01-03 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
US10610664B2 (en) | 2015-07-20 | 2020-04-07 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11471583B2 (en) | 2015-07-20 | 2022-10-18 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
US11420014B2 (en) | 2015-07-20 | 2022-08-23 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
US11229771B2 (en) | 2015-07-20 | 2022-01-25 | Roivios Limited | Percutaneous ureteral catheter |
US10639022B2 (en) * | 2015-11-03 | 2020-05-05 | W. L. Gore & Associates, Inc. | Endoscopic organ manipulation devices and methods |
JP2019500924A (en) * | 2015-11-03 | 2019-01-17 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | Endoscopic organ manipulation device and method |
CN108541218A (en) * | 2015-11-03 | 2018-09-14 | W.L.戈尔及同仁股份有限公司 | endoscope organ manipulation device and method |
EP3370642B1 (en) * | 2015-11-03 | 2024-01-03 | W. L. Gore & Associates, Inc. | Endoscopic organ manipulation devices and methods |
WO2017079124A1 (en) * | 2015-11-03 | 2017-05-11 | W. L. Gore & Associates, Inc. | Endoscopic organ manipulation devices and methods |
US20170119365A1 (en) * | 2015-11-03 | 2017-05-04 | W. L. Gore & Associates, Inc. | Endoscopic organ manipulation devices and methods |
US11160960B2 (en) * | 2016-09-19 | 2021-11-02 | Boston Scientific Scimed, Inc. | Anastomotic drainage stent |
KR20190056395A (en) * | 2016-09-19 | 2019-05-24 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Anastomosed drainage stent |
JP2019522556A (en) * | 2016-09-19 | 2019-08-15 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Anastomosis drainage stent |
KR102280165B1 (en) * | 2016-09-19 | 2021-07-20 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | anastomotic drainage stent |
EP3457952B1 (en) * | 2016-09-19 | 2020-12-30 | Boston Scientific Scimed, Inc. | Anastomotic drainage stent |
US20180078745A1 (en) * | 2016-09-19 | 2018-03-22 | Boston Scientific Scimed, Inc. | Anastomotic drainage stent |
US11134830B2 (en) * | 2016-12-27 | 2021-10-05 | Boston Scientific Scimed, Inc. | Medical device delivery system and methods of use |
US10779967B2 (en) | 2017-03-30 | 2020-09-22 | Boston Scientific Scimed, Inc. | Stents with dual tissue-wall anchoring features |
KR20230158630A (en) | 2017-03-30 | 2023-11-20 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Stents with dual tissue-wall anchoring features |
US11724075B2 (en) | 2017-04-18 | 2023-08-15 | W. L. Gore & Associates, Inc. | Deployment constraining sheath that enables staged deployment by device section |
EP3624729A4 (en) * | 2017-05-19 | 2020-03-25 | Mayo Foundation for Medical Education and Research | Methods and materials for treating urinary calculi |
US11389287B2 (en) | 2017-05-19 | 2022-07-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating urinary calculi |
US11540933B2 (en) | 2017-10-11 | 2023-01-03 | W. L. Gore & Associates, Inc. | Implantable medical device constraint and deployment apparatus |
JP2020092948A (en) * | 2018-12-14 | 2020-06-18 | 住友ベークライト株式会社 | Anchor stent |
KR20200126047A (en) * | 2019-04-29 | 2020-11-06 | 인제대학교 산학협력단 | Balloon fixation type peritoneum-bladder shunt catheter for intraperitoneal ascites drain to bladder |
KR102224302B1 (en) * | 2019-04-29 | 2021-03-05 | 인제대학교 산학협력단 | Balloon fixation type peritoneum-bladder shunt catheter for intraperitoneal ascites drain to bladder |
WO2021055266A1 (en) * | 2019-09-19 | 2021-03-25 | Edwards Lifesciences Corporation | Low-stress compressible implants |
CN110916851A (en) * | 2019-11-29 | 2020-03-27 | 复旦大学附属中山医院 | Universal heart valve intervention forming system |
CN112972784A (en) * | 2021-02-05 | 2021-06-18 | 首都医科大学附属北京世纪坛医院 | Pancreatic juice complete external drainage pancreas duodenectomy and pancreatic juice drainage back transfusion device |
US11918754B2 (en) | 2021-02-11 | 2024-03-05 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
Also Published As
Publication number | Publication date |
---|---|
WO2009073507A2 (en) | 2009-06-11 |
WO2009073521A3 (en) | 2009-09-11 |
US9282968B2 (en) | 2016-03-15 |
GB2460287A (en) | 2009-11-25 |
US9486219B2 (en) | 2016-11-08 |
US20090143760A1 (en) | 2009-06-04 |
EP2222364A2 (en) | 2010-09-01 |
US20110071566A1 (en) | 2011-03-24 |
WO2009073521A2 (en) | 2009-06-11 |
EP2222364A4 (en) | 2012-03-28 |
WO2009073515A2 (en) | 2009-06-11 |
US20110071350A1 (en) | 2011-03-24 |
WO2009073507A3 (en) | 2009-08-06 |
WO2009073515A3 (en) | 2009-08-06 |
US20090143759A1 (en) | 2009-06-04 |
US20120289880A1 (en) | 2012-11-15 |
US20120296257A1 (en) | 2012-11-22 |
GB0821930D0 (en) | 2009-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9486219B2 (en) | Biliary shunts, delivery systems, methods of using the same and kits therefor | |
US9901347B2 (en) | Biliary shunts, delivery systems, and methods of using the same | |
US20170072173A1 (en) | Inflatable translumenal shunts and methods and devices for delivery | |
US8801647B2 (en) | Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks | |
US8403877B2 (en) | Systems and methods for treatment of obesity and type 2 diabetes | |
EP2643044A1 (en) | Biliary shunts, delivery systems, and methods of using the same | |
JP2018183650A (en) | Closer and anastomotic device | |
US8591452B2 (en) | Systems and methods for treating obesity and type 2 diabetes | |
US20110004146A1 (en) | Systems and Methods for Treating of Obesity and Type 2 Diabetes | |
JP2017515631A5 (en) | ||
US20110118765A1 (en) | Anastomosis stent | |
JP2009542349A (en) | Short-circuit device to treat obesity by extracting food | |
US20190321157A1 (en) | Devices and methods to treat gallstone disease | |
US20100100105A1 (en) | Apparatus and method for treating occluded infection collections of the digestive tract | |
AU2019242546B2 (en) | Flow control valve | |
US10292854B2 (en) | Gastrointestinal tract bypass devices | |
US20110004234A1 (en) | Systems and Methods for Treatment of Obesity and Type 2 Diabetes | |
US8911392B2 (en) | Systems and methods for treatment of obesity and type 2 diabetes | |
US20220125434A1 (en) | Single anastomosis gastrointestinal tract bypass endoscopic systems and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TREUS MEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAM, JACQUES VAN;OHLINE, R. MATTHEW;MILROY, J. CRAIG;REEL/FRAME:022215/0246 Effective date: 20090109 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |